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REACTIVITY OF ANTI-GROUP A TYPE 12 STREPTOCOCCAL 
CELL MEMBRANE MONOCLONAL ANTIBODY TO HUMAN 
GLOMERULAR BASEMENT MEMBRANE 
Infection with group A nephritogenic streptococci has long been 
associated with development of sequelae diseases such as 
poststreptococcal glomerulonephritis (PSGN). The etiology of PSGN 
is unknown, but postulated to be mediated by immune complex 
deposition in the GBM or mediated by antibodies evoked by 
streptococcal cell membrane (SCM) which react with a shared epitope 
in the glomerular basement membrane (GBM). A murine mAb was 
produced against group A type 12 SCM and was hypothesized to react 
with human renal cortical tissue and isolated GBM. This mAb, IIF4, 
was examined for reactivity with a panel of 26 human, isolated, 
enzyme digested GBMs. IIF4 reacted with all digests of GBM digests 
(trypsin, collagenase or pepsin) equivalently and with all 26 GBMs 
to a significantly greater extent than an isotype matched mAb did 
with the GBMs. Two groups of GBMS were indicated when extent of 
IIF4 reactivity was examined. IIF4 was hypothesized to react with 
a component of GBM and was established to react with collagen IV, 
which is a major component of the GBM. IIF4 did not react with 
fibronectin, laminin or heparan sulfate proteoglycan or collagen I. 
Attempts were made to identify the location of the epitope on the 
collagen IV molecule. Generally, IIF4 reacted with polypeptides of 
120 and 100 kDa from collagenase digested GBM or collagen IV and 
polypeptides of 100 kDa from pepsin digested GBM. These 
polypeptides were analyzed for amino acid content and each 
contained a high number of cysteine residues (15-30). The size and 
cysteine content of these and similarly sized polypeptides from 
pepsin digested collagen IV was consistent with the IIF4 reactive 
polypeptide as part of the triple helical domain and the NCl domain 
and the IIF4 reactive site as a globular portion of a collagen IV 
polypeptide. The significance of reactivity of an anti-SCM mAb 
with collagen IV is discussed with regard to molecular mimicry as 
it pertains to autoimmune disease and development of PSGN. 
ACKNOWLEDGMENTS 
I would like to thank my mentor, first and foremost, Dr. 
Charles F. Lange, for encouraging, teaching, advising, and 
supporting me. 
I would like to thank the members of my committee, Dr. 
Charles F. Lange, Dr. Thomas M. Ellis, Dr. Rajinder P. Nayyar, Dr. 
Herbert L. Mathews, and Dr. H. Terry Wepsic, for their patience, 
understanding, time, help, consideration, encouragement, sharing of 
knowledge, willingness to teach, and oh yes, more patience. 
A special thanks to Maria Weber for being there and being a 
friend in need. I would like to thank the members of my 
laboratory, Edward J. Fitzsimons, Jr., Phyllis Morenic-Pischl, and 
Mark E. Zelman. I would like to thank the faculty of the 
Microbiology and Immunology department for their support and 
encouragement. I would like to thank the departmental staff: Bill 
Birch, Jerry Glotzer, Charmaine Zawitaj, Jan Makowski, Louise 
Dorsey, and Shelia Honda. I especially would like to thank all the 
graduate students, past and present, for their camaraderie. 
iii 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES •....•.•.•.....••..•...••...•.•...•.•.......... viii 
LIST OF ILLUSTRATIONS ix 
LIST OF ABBREVIATIONS xi 
INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . • • • . • . . . • . . . . . . . . . . . . • 1 
LITERATURE REVIEW .....................•.• , • . . . . . . • • • . • . . . . . . . 3 
METHODS AND MATERIALS • . • . . . . . • • . . . . • • . • • • . . . . . . . . . . . • . . . . . . . . 19 
Production of Ascites from Mice 19 
Isotyping of Ascites and Sera......................... 19 
Euglobulin Precipitation of Ascites ................... 20 
Quantitation of Murine IgM •.•..•...•........••.•...... 20 
Quantitation of Murine IgGl .•..••....•..•...........•. 21 
Protein Determination 21 
Examination of Tissue for Antibody Binding............ 22 
Cryostat Sectioning of Frozen Tissue.................. 22 
Inununofluorescence staining of Tissue................. 23 
Photography of Inununofluorescently Stained Tissue..... 23 
Growth of GS-5 streptococcus mutans ••.•..•..••••.....• 24 
Preparation of Group A Type 12 Streptococci ........... 25 
Preparation of Bacterial Cell Membrane •.•............. 25 
Rhamnose Determination of Cell Membrane ••..•..•....... 26 
Trypsin Digestion of Bacterial Cell Membrane.......... 27 
iv 
Isolation of Human Glomeruli ••...••.••••••••.••.•••.•• 28 
Enzyme Digestion of Human GBM or collagen............. 29 
Amino Acid Analysis 30 
Enzyme Linked Immunoaorbant Assay..................... 30 
Competitive Inhibition of IIF4 Reactivity............. 31 
A. Streptococcal cell membranes as competitors...... 31 
B. Fibronectin, heparan sulfate proteoglycan, 
laminin, and bovine serum albumin as competitors • 32 
c. Enzyme digests of collagen I, collagen IV, 
and GBM as competitors............................ 32 
Competitive Inhibition of Anti-Collagen 
IV mAb Reactivity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 
SDS-PAGE of Proteins • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • . • • 33 
Staining and Duplicating of Protein Gels.............. 34 
Elution of Proteins from SOS-PAGE ••••••••••••••••••••• 35 
Immunoprecipitation 35 
Preclearing of Immunoprecipitable Material............ 36 
Silver Staining of SOS-PAGE . • • • • • . . . . • . . • • • . • • . • . • • • • • 37 
RESULTS • • • . • • • • . . • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 38 
Anti-SCM mAb is IgM Isotype 38 
Reactivity of IIF4 with SCM and 
.§.. mutans Cell Membrane • • • • • • • • • • • • • • • • • • • • • . . • • • • . • 38 
Competitive Inhibition of IIF4 Reactivity with 
SCM and.§.. mutans Cell Membrane ••..•.•.••••.••••.••. 40 
Anti-SCM mAb Binding is Localized to GBM •••••.•••••••. 45 
Amino Acid Analysis of 25 GBMs • • • • • • . • • . . • • • • • • • • . • • • • 45 
Reactivity of Anti-SCM mAb with Isolated GBM 45 
IIF4 Reactivity with Trypsin or Collagenase 
Digested GBM . . . • . • • • • . • • . • . • • • . • . . • . • • • • • . • • • • • . . • • . 49 
Bimodal Distribution of IIF4 Reactivity with 26 GBMs •• 56 
v 
Comparison of IIF4 Reactivity among Bacterial Cell 
Membranes, Isolated Proteins Comprising the GBM, 
and GBM • . . . • • • • • • • • • . • . . . • . . . • • • • • . • • • . . • • • • • • . . . • . • 56 
Conformation of IIF4 Reactivity with Collagen IV....... 58 
A. IIF4 Reactivity is not Inhibited by Laminin, 
Heparan Sulfate Proteoglycan, or 
Bovine Serum Albumin............................. 58 
B. IIF4 Reactivity is Inhibited by Collagen IV...... 59 
C. IIF4 Reactivity with Pepsin Digested Collagen IV 
is Inhibited by. Trypsin Digested SCM and 
Pepsin Digested Collagen IV • • • • • • • • • • • • • • • . • • • . . • 62 
D. Summary of IIF4 Inhibition by Bacterial 
Membranes, GBMs, and GBM Components ..•••••..•..•. 62 
IIF4 Reactive Polypeptides in Collagen IV and GBM •.••.. 68 
A. Immunoprecipitation of GBM Polypeptides 
with IIF4 • • • . . • • • . • . . • . • . . . . . • • • • • • • • • • • . . . . • . . . • 68 
B. Polypeptides from Collagenase Digested 
Collagen IV Reactive with IIF4 ..•••..••••..•...•. 83 
Amino Acid Analysis of IIF4 Reactive Polypeptides •.••.. 84 
Anti-Collagen IV mAb Reactivity with GBM •••••••......•• 92 
Comparison of Anti-Collagen IV mAb Reactivity 
among Bacterial Cell Membranes, Isolated Proteins 
Comprising the GBM, and GBMs • . . . • • • • • • • • • . • • . . • • . . . . 92 
Anti-Collagen IV mAb Reactivity with Trypsin or 
Collagenase Digested GBM .....••.••.••••.•••.•••••... 100 
Competitive Inhibition of Anti-Collagen IV mAb ••••.••.. 100 
DISCUSSION . . . . . . . • • . • . . . . . . . . . . . • . • • . • . • • • • • • • . . . • • . . . . . . . • • . 109 
Characterization and Reactivity of Anti-SCM mAb •••••.. 111 
Characterization of GBMs and IIF4 Reactivity 
with GBMs • • • . . . . • • • • • • . . . . • . • • • • . • . • • • • . • • • • . • • • • . . • 113 
Characterization of IIF4 Reactivity with Components 
of GBM . . . . . . . . . . . . • . . • . . • . . • . . . . . . . . . . • • • . • • • . • . • • . . 118 
Characterization of IIF4 Reactive Polypeptides 
in GBM and Collagen IV •..•..••••...••...•••••••...•• 123 
Reactivity of Anti-Collagen IV mAb with GBM •••••••..••• 129 
vi 
Significance of IIF4 Reactivity with Collagen IV •.•••.. 130 
1. Significance of Anti-SCN mAb Reactivity with 
Collagen IV in Molecular Mimicry ••.......••.••.•• 130 
2. Development of Poststreptococcal 
Glomerulonephritis •...•.....••.•.••..•••..••...•. 131 
Model for Development of Poststreptococcal 
Glomerulonephritis .•.•.......••••...••••.•••........ 134 
SUMMARY 136 
LITERATURE CITED . • • . . • • . . •.. . . • • • . • . • . . • • • . • • • • . . . . • . . . . . . • • . • 138 
VITA • • • . . . . • • . . . . . . • • • • . • • • • • . • • • • . . • • . • • • • • • • . • • • • • • • . • . . . • • 150 
APPROVAL SHEET • . . • . • • • . • • . • • • • • • • . • • . • • . • . . • • • • • • . • • . • • • . . . . . 151 
vii 
LIST OF TABLES 
Table Page 
1. Isotype of murine monoclonal antibodies 39 
2. Amino acid composition of human 
glomerular basement membrane........................... 48 
3. Summary of competitive inhibition 
studies, inhibition of IIF4 
reactivity • • • . . . . . . . . . • . . . . . . . • • • • . • • • • . • • . • . . • . • . . . • • . 69 
4. Summary of immunoprecipitation data 
5. Summary of competitive inhibtion 
studies, inhibition of anti-collagen 
91 
IV mAb reactivity •.•.•••••...••. •••••...••..••.•••...••. 108 
viii 
LIST OF ILLUSTRATIONS 
Figure 
1. Reactivity of IIF4 with trypsin digested 
Group A type 12 SCM and trypsin digested 
cell membrane from ~· mutans 
2. competitive inhibition of IIF4 reactivity 
Page 
42 
with bacterial cell membranes •••••••••.••••••••••••..••• 44 
3. Indirect irnmunofluorescence of human renal 
cortical tissue with IIF4 and TEPC 183 ••.•••••••••.••.•. 47 
4. IIF4 reactivity with 26 human GBMs •.•.....•.••.••.•••.•••• 51 
5. IIF4 does not react differently to trypsin 
or collagenase digested GBMs ••••••••.•........•.•••••.•• 53 
6. Bimodal distribution of IIF4 reactivity 
with 26 GBMs • • • • • • • • • • . • • • • • • • • • • • • • • • • • . . . • . • • . • • • . . • . . 55 
7. Comparison of IIF4 reactivity with 
streptococcal cell membranes, isolated 
components of GBM and GBM • • • • . • • • • • • • • • • • • . . . • • • • • • • • • • • 61 
8. Competitive inhibition of IIF4 reactivity 
with isolated proteins from the GBM ••••••••.•.••••.••.•• 64 
9. Competitive inhibition of IIF4 reactivity................. 66 
10. Irnmunoprecipitation of collagenase digested 
GBM polypeptides with IIF4 ••••••••••·••·•··••·••••··•·• 72 
11. Immunoprecipitation of polypeptides from 
collagenase digested GBMs 7415 N and 19763 N •..•••...•• 74 
12. Irnmunoprecipitation by IIF4 of polypeptides 
from collagenase digested GBM 11778 N •••••••••••••••••. 76 
13. Irnmunoprecipitation by IIF4 of polypeptides 
from collagenase digested GBM 9662 N •••••.••••••••••••• 78 
ix 
14. Immunoprecipitation by IIF4 of polypeptides 
from collagenase digested GBM 8961 N •••••.•••••••..•••. 80 
15. Immunoprecipitation by IIF4 of polypeptides 
from pepsin digested GBM ••••••.•••••••••••••••..••••••. 82 
16. Immunoprecipitation by IIF4 of polypeptides 
from collagenase digested collagen IV •••.••••••.•••••.• 86 
17A. Immunoprecipitation by IIF4 of polypeptides 
from pepsin digested collagen IV...................... 88 
17B. IIF4 did not immunoprecipitate any polypeptides 
from pepsin digested collagen I or laminin •••••.••.••• 90 
18. Amino acid profile of polypeptides from 
collagenase digested GBM and collagen IV............... 94 
19. Amino acid profile of polypeptides from 
pepsin digested GBM and collagen IV.................... 96 
20. Indirect immunofluorescence of human renal 
cortical tissue with anti-collagen IV mAb 
21. Anti-collagen IV mAb reactivity with bacterial 
membranes, isolated components of the GBM, 
98 
and GBMs • • . • . • . . . . • • . . • • . . • • • . • • . • . . . • • • . • . . . . • • . • • . . . . 102 
22. Trypsin digested GBM and collagenase digested 
GBM did not react equally with anti-collagen IV mAb ..•• 105 
23. Competitive inhibition of anti-collagen IV mAb 
with collagen I and IV, fibronectin, and 
trypsin digested SCM • . • • • • • • • • • • • • • • • . • • • • • • • • • • • • . • • . • 107 
x 
ASPGN 
BCA 
BSA 
ELISA 
GBM 
kDa 
ug 
mg 
M 
MW 
mAb 
ng 
nm 
O.D. 
PMSF 
PBS 
PSGN 
RT 
sos 
SOS-PAGE 
SCM 
LIST OF ABBREVIATIONS 
Acute Poststreptococcal Glomerulonephritis 
Bicinchoninic Acid 
bovine serum albumin 
Enzyme Linked Immunosorbent Assay 
glomerular basement membrane 
kilodalton 
microgram 
milligram 
molar 
molecular weight 
monoclonal antibody 
nanograms 
nanometers 
optical density 
phenylmethyl sulfonyl fluoride 
phosphate buffered saline 
poststreptococcal glomerulonephritis 
room temperature 
sodium doceyl sulfate 
sodium doceyl 
electrophoresis 
sulfate 
Group A type 12 
streptococcal cell membrane 
xi 
polyacrylamide gel 
TEMED 
TSB 
v 
N,N,N',N'-Tetramethylethylenediamine 
tryptic soy broth 
volts 
xii 
INTRODUCTION 
The clinical association between streptococcal infection and 
subsequent development of glomerulonephritis has long been 
established (Futcher, 1940; Rammelkamp, Weaver, and Dingle, 1952; 
stollerman, 1969). Streptococci are grouped by surface 
polysaccharides; in group A, streptococci are serologically typed by 
surface M protein. Clinically, in the United states, of over 70 M 
types, ten have been termed nephritogenic (Stollerman, 1969). 
Infection with one of these types of streptococci can lead to 
complications of glomerulonephritis. A question that our laboratory 
would ultimately like to answer is what is the nature of the 
association between infection with a nephritogenic strain of 
streptococci and development of glomerulonephritis. Experimental 
immunochemical evidence, gathered in our laboratory over the last 
twenty years, has pointed to an antigenic relationship between the 
cell membrane of group A type 12 streptococci and a component of the 
glomerular basement membrane (Markowitz and Lange, 1964; Lange, 
1980b). In order to examine this question more closely, murine 
monoclonal antibodies were generated to group A type 12 SCM 
(Fitzsimons, Weber, and Lange, 1987). Screening and clone selection 
2 
was based on the ability of the monoclonal antibody to display 
reactivity to both pooled glomerular basement membrane antigen as 
well as streptococcal cell membrane antigen. One of these 
monoclonal antibodies, IIF4, was chosen for use in this study of the 
glomerular antigen related to an SCM antigen. 
LITERATURE REVIEW 
Streptococci are grouped by surface polysaccharide. In beta 
hemolytic, group A streptococci (the major pathogenic group), 
streptococci are typed by surface M protein; this work was 
accomplished by Lancefield ( Stollerman, 1975). There are over 70 
serologic types of group A streptococci and of these 70, ten have 
been clinically correlated with nephritis. In the United States, 
types 1, 2, 4, 12, 18, 25, 49, 55, 57, and 60 are termed 
nephritogenic (Stollerman, 1969). Type 12 has been most frequently 
associated with pharyngeal infections leading to glomerulonephritis. 
This clinical correlation between infection with streptococci and 
development of glomerulonephritis was first noted by Richard Bright 
in the early 19th century after a patient developed nephritis 
following an upper respiratory infection and scarlet fever 
(Williams, 1987). Subsequently, group A nephritogenic streptococci 
were implicated in the development of glomerulonephritis, rheumatic 
fever and skin diseases such as impetigo and scarlet fever following 
infection of the pharynx or skin (Futcher, 1940; Zabriskie, 1971; 
Rammelkamp, Weaver, and Dingle, 1952). 
Infection with a nephritogenic strain of streptococci and 
subsequent development of life-threatening nephritis is a rare 
occurrence in the United States. However, in the developin9 third 
3 
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world countries, these sequelae diseases pose serious problems for 
health care workers and serious health problems for children, 
especially in tropical climates (Williams, 1987; Rodriguez-Iturbe, 
1984; Sorger et al., 1987; Fischetti, 1989). 
The M protein classifies the serotype of the streptococci; 
however, streptococci are defined as nephritogenic if that M type of 
streptococci is isolated from a patient who developed acute 
glomerulonephritis (Rodriguez-Iturbe, 1984). It is known that a 10-
15% incidence of glomerulonephritis results after nephritogenic 
streptococcal infection (Anthony et al., 1969; Dillon, 1972) and 
this attack rate is related to the site of infection. The M protein 
is also the means by which the streptococci escape the host immune 
response. M proteins are long fibril proteins projected from the 
cell wall surface of the streptococci; it is composed of alpha 
helical coiled coil proteins (Beachey, Seyer, and Kang, 1978; 
Phillips et al., 1981). The M protein must be opsonized before host 
phagocytic cells can engulf and destroy the bacteria (Fischetti, 
1989; Beachey et al., 1986). 
M proteins have been shown to share homology with myosin 
(Fischetti, 1989; Krisher and Cunningham, 1985; Dale and Beachey, 
1985; Jones et al., 1986; Cunningham et al., 1989). M protein was 
also reported to share an epitope with the intermediary filament 
vimentin (Kraus et al., 1989) and a 46 kDa component of glomerular 
tissue (Goroncy-Bermes et al., 1987; Kraus and Beachey, 1988). 
Clearly, the M protein is a complex protein with several indicated 
shared epitopes with mammalian tissue. 
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Although the M protein is responsible for host invasiveness, 
what defines a streptococci as nephritogenic? This is an unresolved 
issue (Rodriguez-Iturbe, 1984). Two theories have been generated to 
explain the role of streptococci in the development of 
glomerulonephritis. In the first theory, immune complexes between 
streptococcal components and antibody are formed and then deposited 
in the GBM (Michael et al., 1966; Friedman et al., 1984). 
Circulating immune complexes have been isolated from patients with 
poststreptococcal glomerulonephritis (Van de Rijn et al., 1978; 
Rodriguez-Iturbe 1980; Jennette et al., 1982). 
Alternatively, cationic antigens are deposited in the GBM and immune 
complexes are formed in situ (Vogt et al., 1983; Stinson et al., 
1983). 
In acute poststreptococcal glomerulonephritis, antibodies are 
made against streptococci; this is judged clinically by patient 
serum titers to streptolysin-o, a hernolysin of group A streptococci 
(Sorger et al., 1983; Williams, 1987). Some investigators have 
shown the presence of streptococcal antigen in glorneruli from 
patients with poststreptococcal glornerulonephritis, especially in 
the acute phase of the disease (Yoshizawa et al., 1973; Anders et 
al., 1966; Michael al., 1966; Treser al., 1970). However, the 
streptococcal component of the immune complex or .the immune 
complexes in patients with poststreptococcal glomerulonephritis 
could not always be demonstrated. Furthermore, the nature of the 
immune complex streptococcal component is controversial (Rodriguez-
Iturbe, 1984). 
The second theory postulates that a component 
6 
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nephritogenic streptococci, the cell membrane, and a component of 
the glomerulus, the basement membrane, share a common antigenic 
component (Markowitz and Lange, 1964). The theory predicts that 
antibodies raised to a component of SCM react with GBM. The 
reaction is antibody mediated and therefore may be classified as 
potentially autoimmune. This is based on immunochemical evidence 
which showed that an anti-serum raised to type 12 SCM reacted with 
extracts of human glomeruli; anti-serum raised to glomerular extract 
reacted with SCM (Markowitz and Lange, 1964). A chemical 
relationship between SCM and GBM was indicated by amino acid and 
carbohydrate analysis of GBM and SCM enzyme digest derived fragments 
which were found to be antigenically related through the use of 
anti-SCM and anti-GBM sera (Lange, 1969). These studies indicated 
that SCM and GBM were related antigenically. 
Further evidence of antigenic relatedness was shown with 
anti-SCM serum reactive with GBM in kidney sections (Markowitz and 
Lange, 1964; Blue and Lange, 1975). This activity could be absorbed 
by isolated GBM, or glomeruli, but not with liver or spleen 
homogenates. Likewise, anti-glomerular serum reacted with GBM in 
tissue sections and this activity could be absorbed by SCM. These 
experiments also indicated that the glomerular carbohydrate masked 
the anti-SCM serum reactive sites on murine GBM, particularly in 
relatively carbohydrate rich adult tissue as compared to neonatal 
tissue (Blue and Lange, 1975; Blue and Lange, 1976; Lange, 1980a). 
In general, young human and murine glomerular tissue was more 
7 
reactive with anti-SCM serum in immunofluorescence than adult 
tissue. Thus, an immunochemical basis was established for the 
antigenic relatedness of GBM and SCM. 
In order to investigate the nature of the antigenic 
relatedness between GBM and SCM, anti-SCM serum was used as an 
immunizing agent and a surrogate for streptococcal infections. 
Guinea pigs injected with anti-SCM serum developed necrotic skin 
lesions (Lange, 1973). These studies indicated that the anti-SCM 
serum was responsible for significant skin pathology. Mice injected 
with anti-SCM serum presented with subepithelial granular deposits 
on the GBM as judged by electron microscopy and had incorporation of 
praline into GBM proteins; these proteins were suggested to be a 
noncollagenous glycoprotein and a collagenous protein from rate of 
incorporation (Nayyar, Lange, and Borke, 1985). Anti-SCM serum 
alone was responsible for the skin and renal pathology seen in these 
two reports. 
The pathology seen in human acute poststreptococcal 
glomerulonephritis is characterized by glomerular infiltration by 
neutrophils, and the proliferation of mesangial cells. Also, 
electron dense deposits are located subepithelially or 
subendothelially on the GBM and the presence of C3 and f ibrinogen in 
an irregular deposition pattern on the GBM is noted (Rodriguez-
Iturbe, 1984). Poststreptococcal glomerulonephritis is associated 
with the expression of HLA-DRl, HLA-B7, and HLA-B44 (Naito, Kohara, 
and Arakawa, 1987). This may allow classification of 
poststreptococcal glomerulonephritis with autoimmune diseases such 
8 
as ankylosing spondylitis and Reiter's syndrome. Glomerulonephritis 
can be induced by anti-SCM serum or SCM components. 
Glomerulonephritis was induced in rhesus monkeys actively by 
injections of soluble glycoprotein from SCM or passively by 
injections of antibodies raised against SCM glycoprotein. In both 
cases, clinical signs of glomerulonephritis were present (Markowitz 
, 1971). Mice injected with anti-SCM serum presented kidney 
pathology similar to pathology present in kidney biopsies from 
patients with acute poststreptococcal glomerulonephritis (Nayyar, 
Lange, and Volini, 1985). Presence of neutrophils, increased 
cellularity in the mesangium and subepithelial electron dense 
'humps' were noted. The evidence indicated a direct action of the 
anti-SCM serum on the glomerulus. 
It can be argued that the use of a serum is not specific 
enough to detect common antigens in two discrete proteins. Serum 
contains a mixture of host antibodies directed towards many 
immunogens. Therefore, a series of murine monoclonal antibodies 
generated to group A type 12 SCM were produced and mAbs were 
selected for reactivity with GBM as well as lung basement membrane 
(Fitzsimons, Weber, and Lange, 1987). Isolated murine or human 
enzyme digested (trypsin or collagenase) GBM could inhibit binding 
of several of the rnAbs to its autologous antigen, SCM (Fitzsimons, 
Weber, and Lange, 1987; Zelman and Lange, 1989). These experiments 
indicated that an antigenic relatedness between GBM and SCM existed 
based on the definition of an mAb reacting with a unique, specific 
epitope. 
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The SCM component containing the epitope shared with GBM has 
not been identified, but a tryptic digestion fragment of the 
component was isolated by anti-SCM mAb affinity chromatography. A 
13 kDa polypeptide was isolated, but other, 2.3 to 11.2 kDa, 
polypeptides were noted to bind the anti-SCM mAB affinity column 
when each was isolated by molecular sieving and then passed over the 
affinity column. Relative epitope densities were assigned to each 
polypeptide based on their molecular size and molar ratio of 
polypeptide bound to mAb. Relative epitope density increased with 
the size of the polypeptides. This was interpreted to mean that the 
intact SCM polypeptide consisted of repeating epitopes (Zelman and 
Lange, 1989). 
Evidence based on anti-SCM mAb reactivity with isolated GBM 
indicated that SCM and GBM shared an epitope. However, the GBM 
component containing this common epitope was unknown. Basement 
membranes are complex extracellular matrices composed of several 
proteins. The functions of basement membranes are 
compartmentalization of organs, stability of tissues, inhibition of 
tissue invasion by cells, and filtration of macromolecules. 
Basement membranes are found in kidney, the blood-brain barrier, 
placenta, gut, lung, skin, cornea, and blood vessels and can be 
found encircling muscle, nerve and fat cells (Glanville, 1987). 
Cells surrounding basement membrane generally produce the membrane 
and remain in close contact with the membrane; this is thought to be 
mediated by cellular receptors binding to extracellular matrix 
ligands (Timpl, 1989). 
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GBM is a specialized extracellular matrix which serves as a 
border between the urinary side and the capillary side of the 
glomerular capillary wall. Capillary endothelial side cells are a 
continuous sheet of cells punctuated by fenestrae. Urinary 
epithelial cells have characteristic podocyte morphology and the 
foot processes are separated by filtration slits. Mesangial cells 
face the remaining parts of the membrane. Ultrastructurally, the 
GBM is composed of three layers; the lamina rara externa (urinary 
side), the lamina densa (slightly more electron dense than the other 
layers), and the lamina rara interna (capillary side) (Wieslander, 
1983; Timpl, 1989). Both the endothelial and epithelial cells are 
known to produce extracellular matrix which fuses to form the 
basement membrane (Timpl and Aumailley, 1989). 
The specialized function of the qBM is to ultrafilter the 
blood plasma to begin the process of urine formation. The GBM has 
an overall negative charge and allows proteins of less than 70 kDa 
to filter into the urine (Vogt et al., 1983; Timpl, 1989). The 
electrostatic charge of the plasma proteins is important. Proteins 
of greater than 70 kDa with a pI of greater than 8.5 can accumulate 
in the GBM and form in situ immune complexes with circulating 
antibody (Vogt et al., 1982). The integrity of the GBM is a crucial 
matter; immune complexes or antibody deposited in the GBM can lead 
to an inflammatory response of complement activation, neutrophil 
chemotaxis and lysosomal enzyme release and damage to the GBM 
leading to proteinuria and renal failure in some cases (Rodriguez-
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Iturbe, 1984) . Thus, the integrity of the GBM is an important 
matter. 
The components of the GBM are collagen IV (which is a three 
chain coil) composed of alpha l(IV) and alpha 2(IV) chains, laminin 
which is composed of an A, Bl and B2 chains, nidogen or entactin, 
heparan sulfate proteoglycan, BM-40 and possibly other components. 
(Timpl, 1989; Timpl and Aumailley, 1989). 
Collagen IV is the major component of the GBM comprising 
between 30% and 80% of its total mass. Collagen IV derived from 
human placental membrane and bovine capsular membrane is well 
characterized. Collagen IV is believed to provide the structural 
network for the GBM (Kuhn et al., 1981; Timpl, 1989). Collagen IV 
is a distinct collagen type found only in basement membranes and is 
distinctly different from classical fibril-type interstitial 
collagens I, II, and III (Kefalides, 1973). Collagen IV is the only 
type of collagen (eleven types have been identified) that forms non-
fibrillar networks (Kuhn, 1987). All collagens contain three alpha 
chains which are composed of repeating triplet of glycine-X-Y which 
account for the helical structure of the molecule. Hydroxy lated 
proline and lysine are found interspersed in the X-Y positions and 
are only found in collagen molecules (Kuhn, 1987). 
Collagen IV differs from classical collagens in two major 
characteristics. First, collagens are synthesized as a procollagen 
precursor with globular domains at the amino and carboxyl termini of 
the alpha chain. Three alpha chains wound in a triple helix form 
procollagen. In classical collagens, the globular domains are 
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cleaved by extracellular enzymes and are not incorporated into the 
collagen molecule or fibril. However, in types IV and VI collagen, 
these globular domains are retained. Second, collagen IV has 21 
small, globular interruptions in the three alpha chains; these are 
believed to allow for flexibility of the collagen molecule in 
basement membrane assembly (Kuhn, 1987; Glanville, 1987). 
Mature collagen IV is composed of three alpha chains (each 
with amino and carboxyl globular domains) wound into a superhelix. 
There are four forms of the type IV alpha chain: alpha l(IV), alpha 
2(IV), alpha 3(IV) and alpha 4(IV). Classically, collagen IV 
molecules were thought to be composed of two alpha 1 (IV) and one 
alpha 2 (IV) chain although it is not known if all collagen IV 
molecules in a basement membrane will be composed similarly. 
Collagen IV molecules have been identified with one alpha 1 (IV) 
chain and two alpha 2(IV) chains (Timpl, 1989; Brazel et al., 1988). 
In addition to this heterogeneity, alpha 3 (IV) chains have been 
identified in GBM with alpha l(IV) and alpha 2(IV) chains. The 
occurrence of alpha 3(IV) chains is now thought to be wide spread 
(Timpl, 1989; Hudson al./ 1989) • This greatly increases the 
potential heterogeneity of the collagen IV molecule in a GBM. 
The human alpha l(IV) chain, which is 1669 amino acid 
residues in length, is composed of a signal peptide (amino acids 1-
27), the amino terminal overlap and cross link 7S globular domain 
(28-172), the central alpha helical region (173-1440) and the 
noncollagenous NCl domain (1441-1669) (Brazel et al., 1988). Alpha 
1 (IV) chains from mouse and Drosophila have also been amino acid 
sequenced as well as alpha 2 (IV) in human and mouse. 
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All alpha 
chains have some homology with each other (Timpl, 1989). The 7S 
domain of each alpha chain has a high percentage of hydrophobic 
amino acids as well as 4 cysteine residues and two lysine residues; 
these are responsible for inter- and intramolecular crosslinks with 
other alpha chains and other collagen IV molecules. Another 
cysteine residue (position 98) is exclusively involved in 
intermolecular crosslinks. The number and position of cysteine 
residues are conserved in human alpha l(IV) and alpha 2(IV) chains 
(Glanville, 1987). The NCl domain of an alpha chain has a high 
percentage of hydrophobic amino acids and a total of 12 cysteine 
residues per domain. Two homologous subregions (35\ homology with 
an additional 21\ conservative substitutions) each contain 6 
cysteine residues (Glanville, 1987, Timpl, 1989). 
The function of the two major globular domains of collagen IV 
in basement membrane formation are aggregation (7S domain) and dimer 
formation (NCl domain). Two models for the assembly of the collagen 
IV backbone in basement membranes have been proposed; the network 
and the hexagonal model (Yurchenco, 1990; Timpl, 1989). These two 
theories are based on rotary shadowed electron microscopy of 
isolated collagen IV molecules. In the network assembly model, the 
intact 7S domain consists of the aggregation and overlap of 7S 
domains of 4 collagen IV molecules (12 alpha chains total) and the 
dimer formation of NCl domains from two collagen IV molecules. This 
assembly model leads to a chicken wire-like network of assembled 
collagen IV molecules. In the hexagonal model, self asseriibly is 
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initiated by NCl dimer formation, followed by association of 12 
collagen molecules (36 alpha chains) (Yurchenco, 1990; Glanville, 
1987). Regardless of the correctness of either model, the end 
result is a highly disulfide-stabilized, cross-linked association of 
75 to 75 domains and NCl to NCl domains. This forms the backbone of 
the basement membrane. 
Another major GBM component is laminin. Murine laminin is 
best characterized. Laminin (800 kDa) is composed of three 
disulfide-linked polypeptides chains: Bl and 82 (200 kDa each) and A 
(400 kDa with isoforms). These chains are folded into a cross-like 
structure with 3 short arms and one long arm. Each arm has globular 
and rod-like domains with marked alpha helical domains at the 
carboxyl terminus of each arm. Each of the 4 arms are homologous in 
1200 amino acids at their amino termini. The short arms are 
cysteine rich and have similarity to epidermal growth factor. In 
addition, the long arm has a unique globular domain at its carboxyl 
terminus distal to the junctional region of the cross (Timpl and 
Aumailley, 1989; Ekblom et al., 1990; Abrahamson et al., 1989). 
Laminin has several binding and biologic properties. Nidogen, a 150 
kDa single polypeptide chain with a dumbbell shape, is stably, 
noncovalently bound to laminin in an equimolar ratio with the short 
arm of laminin (Timpl, 1989; Mann et al., 1989). Nidogen may be 
identical to entactin, a sulfated 15 kDa protein found in cell 
cultures (Mann et al., 1989). It has been suggested that 
nidogen/entactin mediates laminin binding to collagen IV (Timpl, 
1989). On the opposite short arm from nidogen, is a cell binding 
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site; another cell binding site is located on the globular end of 
the long arm. Although this has not been proven for laminin, the 
cell binding sequence, arginine-glycine-asparagine (RGD) has been 
demonstrated in collagen IV. The RGD sequence mediates cell binding 
in fibronectin, vitronectin, von Willebrand factor, osteopontin, 
integrins, nidogen and collagen I (Timpl and Aumailley, 1989; 
Pierschbacher and Ruoslahti, 1984; Mann et al., 1989). The globular 
domain of the long arm has also been implicated in heparin binding 
(Timpl, 1989; Martin and Timpl, 1987). Like collagen IV, laminin 
molecules can polymerize which may contribute to the assembly of the 
basement membrane (Yurchenco and Furthmayr, 1984). 
The major proteoglycan in GBM is heparan sulfate 
proteoglycan; murine and human heparan sulfate proteoglycan have 
been characterized. There are two forms of heparan sulfate 
proteoglycan: low and high buoyant density. The protein core for 
the low density form (30% by weight carbohydrate) is 480 kDa with 
three heparan sulfate chains attached to it. The heparan sulfate 
chains (in human) are each 18 kDa and are anionic (Van Den Heuvel 
al., 1989; Timpl, 1989; Schleicher et al., 1989). Polyanionic 
heparan sulfate proteoglycan is believed to give the basement 
membrane the majority of its negative charge. Small heparan sulfate 
proteoglycans (high density) have also been identified in the GBM; 
these star-shaped molecules (130 kDa) have a protein core with four 
heparan sulfate chains attached (Edge and Spiro, 1987; Timpl, 1989). 
Chondroitin sulfate proteoglycan and dermatin sulfate proteoglycan 
have been identified in small amounts in the GBM by chemical 
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characterization and immunochemical localization (Paulsson et al., 
1985) • 
Formation of the basement membrane is dependent on divalent 
cations, especially calcium. Laminin polymerization is calcium 
dependent (Yurchenco and Furthmayr, 1984) and the association of 
laminin and nidogen is calcium dependent (Paulsson et al., 1987). 
Another calcium dependent basement membrane protein is BM-40 (also 
called osteonectin or SPARC) which is a single chain 35 kDa protein. 
BM-40 binds calcium and is ubiquitous in basement membranes (Timpl 
and Aumailley, 1989). 
In total, the GBM is a complex structure of heterogeneous 
collagen IV, laminin, nidogen/entactin, heparan sulfate proteoglycan 
with small amounts of other proteoglycans, BM-40 and possibly other 
unidentified components. The exact percentages of each component in 
a basement membrane are unknown and, in the GBM, may vary with the 
age of the individual. Also, the exact mechanism of GBM assembly is 
unknown and therefore the ultrastructural localization of each 
component is not fully understood (Yurchenco, 1990; Yurchenco et 
al. I 1986) • The importance of the integrity and maintenance of 
function of the GBM is, however, indisputably critical. 
Important characteristics of the GBM are its antigenicity and 
immunogenicity. In experimental nephritis, a proliferative 
glomerulonephritis can be induced by injection of heterologous GBM 
into sheep (Steblay, 1962). This evidence along with many other 
reports (Unanue and Dixon, 1965; Dixon, Feldman, and Vasguez, 1961; 
Hammer and Dixon, 1963; Hoedemaeker et al., 1972), established the 
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antigenicity and immunogenicity of GBM and its ability to initiate 
nephrotoxic disease. This experimental system attempts to parallel 
the conditions in some human glomerulonephritis. Patients with 
glomerulonephritis possess antibodies reactive with GBM (Wieslander, 
Bygren and Heinegard, 1983; Wilson and Dixon, 1974; Lerner, 
Glasscock, and Dixon, 1967) although the exact target of these 
antibodies is not determined (Wieslander, Bygren and Heinegard, 
1983). In Goodpasture syndrome, which has glomerular and pulmonary 
hemorrhagic involvement, autoantibodies are directed to a specific 
component of collagen IV (Wieslander et al., 1984; Kefalides et al., 
1986; Pusey et al., 1987). Serum from a Goodpasture patient reacts 
specifically with the NCl portion of the alpha 3 (IV) chain (Hudson 
et al., 1989). The specific portion of the NCl domain reactive with 
Goodpasture sera is a 26 kDa monomer (designated M2*) which is a 
noncollagenous polypeptide believed to be sequestered within the 
hexameric structure of the NCl domain. There is also reactivity to 
an apparently nonreduced 52 kDa dimer (Wieslander, Kataja, and 
Hudson, 1987; Pusey et al., 1987; Weber, Meyer zum Buschenfelde, and 
Kohler, 1988) • Reactivity of the Goodpasture serum to collagenase 
digested collagen IV or basement membrane from bovine lens capsule, 
lung, or placenta or human placenta, lung, or glomeruli indicated 
that the Goodpasture antigen is widespread (Weber et al., 1987; Fish 
et al., 1984; Weber, Meyer zum Buschenfelde, and Kohler, 1988; 
Wieslander, Kataja, and Hudson, 1987). It has been speculated that 
the Goodpasture antigen is sequestered, masked or otherwise 
privileged and only revealed after dissociation of the NCl hexamer 
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by toxic, infective or other traumatic episode (Weber, Meyer zum 
suschenfelde, and Kohler, 1988). The Goodpasture autoantigen is the 
most studied of the defined glomerular antigens. 
Another GBM antigen involved in an autoimmune disease, IgA 
nephropathy, has been suggested to be part of the alpha helical 
portion of collagen IV. Patient IgA antibodies react with the 
triple helical portions of the alpha chains (reactivity was 
destroyed by collagenase digestion) of collagen IV, collagen I and 
collagen II after pepsin digestion (Cederholm et al., 1986). The 
autoantigen in familial Alport syndrome involves collagen IV. It 
has been found that the basement membrane in Alport patients do not 
have a 'normal' 28 kDa monomer integrated in the NCl domain. 
Evidence points to a different NCl monomer in the alpha 3(IV) chain 
that is the autoantigen (Kleppel et al., 1989). This autoantigen is 
closely related to the Goodpasture antigen (Savage et al., 1986) • 
Thus, collagen IV has been identified as the repository of several 
autoantigens highly associated with specific autoimmune diseases. 
The purpose of this thesis is to determine the reactivity of 
an anti-SCM mAb with human GBM. The association of nephritogenic 
streptococcal infection and development of glomerulonephritis has 
been established along with the autoantigenic qualities of several 
GBM antigens. This thesis seeks to investigate the immunochemical 
link between SCM and GBM by examining the reactivity of anti-SCM mAb 
with a panel of human GBMs and to identify the anti-SCM mAb reactive 
component in GBM. 
METHODS AND MATERIALS 
Production of Ascites From Mice 
Ascites containing monoclonal antibody were produced by 
standard methods (Johnstone and Thorpe, 1982). Pristane (2,6,10,14 
tetramethylpentadecane, Aldrich Chemicals, Milwaukee, WI) primed 
Balb/c mice (Jackson Laboratories, Bar Harbor, ME) were injected in-
traperitoneally with lx106 to lxl07 cloned hybridoma cells. 
Hybridoma cells were produced by the fusion of spleen cells from 
Balb/c mice immunized with group A type 12 streptococcal cell mem-
brane and P3-X63-Ag8 nonsecreting plasmacytoma cells (Fitzsimons, 
Weber and Lange, 1987). Twelve to fourteen days post injection, 
mice were sacrificed by ether inhalation, jugular vein severing and 
exsanguination. Blood, ascites and hybridoma cells were recovered 
and heart, kidney and lung tissues collected for examination. 
Isotyping of Ascites and Sera 
Isotyping of ascites and sera was performed via ELISA 
according to manufacturer's instructions (Isotyping kit, HyClone, 
Logan, UT). Briefly, 96 well plates (Becton Dickinson, Oxnard, CA) 
were sensitized with goat anti-mouse immunoglobulins and then 
blocked with 1% BSA in PBS. Ascites or sera (0.1 ug/ml protein of 
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each) were added to wells; a 1:500 dilution of normal mouse serum 
and normal rabbit serum were used as positive and negative controls, 
respectively. After washing, goat anti-mouse IgGl, IgG2a, IgG2b, 
IgG3, IgA, and IgM monoclonal (as supplied by HyClone) antibodies 
were added to the plate. Bound antibodies were detected with alkal-
ine phosphatase labeled goat anti-mouse immunoglobulins and a para-
nitrophenyl phosphate based substrate (both were supplied by 
HyClone). Optical density of individual wells was read at 405 nm 
with a microplate reader (MR-600, Dynatech, Alexandria, VA). Reac-
tions were considered positive when above 0.600 optical density. 
Euglobulin Precipitation of Ascites 
Euglobulin fractionation of ascites is a quick and gentle 
process to isolate IgM from sera or ascites (G rcia-Gonz les, et 
al., 1988). Ascites was placed in dialysis tubing, 10,000 molecular 
weight cutoff (Union Carbide, Chicago, IL), and dialyzed versus dis-
tilled water for 18 hours at 4°c. Recovered material was then 
centrifuged (Eppendorf, Brinkmann) for 3 minutes. The recovered 
precipitate was the solubilized in borate buffered saline, pH 8. 5 
(0.1 M boric acid, 25 mM sodium tetraborate, 75 mM NaCl) at 4°c. 
Quantitation of Murine IgM 
For ELISA, 96 well plates were sensitized with goat anti-
mouse IgM (0.1 ug/ml) (HyClone) in 0.05 M carbonate buffer, pH 9.6 
for 18 hours at room temperature (RT) and then blocked with 1% 
bovine serum albumin in phosphate buffered saline (PBS), pH 7.4 for 
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3 hours. After washing, dilutions of the sera, ascites or euglobu-
lin fractions were applied to the plate. TEPC 183 (murine myeloma, 
IgM, Sigma, St. Louis, MO) was applied to the plate in dilutions of 
20 ug/ml to 0.016 ug/ml. After incubation and washing, goat anti-
mouse IgM conjugated to peroxidase was applied to the plate at 0.1 
ug/ml. After incubation and washing, substrate [equal parts of 
0.02% 2,2' -azinodi-(3-ethylbenzthiazoline sulfonic acid, Sigma) in 
O.l M citrate buffer, pH 4.1 and 0.01% H202 in PBS) was applied to 
the plate and the optical density read at 405 nm in the microplate 
reader at 30 minutes. A standard curve of TEPC 183 concentration 
versus optical density was generated and the IgM concentration of 
the sera, ascites or euglobulin fractions was read from this curve. 
Quantitation of Murine IgGl 
Quantitation of anti-collagen type IV monoclonal antibody 
(mAb) was accomplished using MOPC 21 (murine myeloma, IgGl, Sigma) 
and the same methodology as previously described for murine IgM 
except that peroxidase labeled goat anti-mouse IgG was used as the 
detecting antibody and the 96 well plate was sensitized with 0 .1 
ug/ml goat anti-mouse immunoglobulins in 0.05 M carbonate buffer, pH 
9.6. 
Protein Determination 
The bicinchoninic acid (BCA) protein determination assay is 
based on the interaction of protein and copper ion (Cu+2 ) in 
alkaline solution to produce cuprous ion (Cu+l); this ion interacts 
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with BCA to form a colored reaction product. Bovine serum albumin 
(BSA) ( 1000 ug/ml to 15. 7 ug/ml) are applied to a 96 well plate 
along with dilutions of the unknown. The BCA reagents are applied 
to the plate according to the manufacturer (Pierce Chemicals, 
Rockford, IL) and incubated at 37°c for 30 minutes. Absorbance was 
read at 560 nm in the microplate reader. A standard curve of BSA 
concentration was produced and the concentrations of the unknowns 
were read from the curve. 
Examination of Tissue for Antibody Binding 
Human kidneys (whole or sections) were obtained from National 
Diabetes Research Interchange, Philadelphia, PA. All tissues were 
negative for HIV and Hepatitis B virus. Tissues were collected upon 
autopsy and no tissue was used in this study from any individual 
with overt kidney disease. Age at time of death was 56 ± 19 years; 
this study used the tissue from 16 males and 11 females. Cortical 
sections were embedded in O.C.T. compound, quick frozen, and held at 
-10°c until use. 
Cryostat Sectioning of Frozen Tissue 
Tissue sections embedded in o.c.T. compound were mounted on 
brass buttons and warmed to -3o0 c in the cryostat (International 
Equipment co., Needham, MA). Sections of 3 microns were cut and 
dried onto methanol cleaned and Histostik (Accurate Chemical, 
Westbury, NY) coated glass slides. Tissue sections were fixed onto 
the slides with acetone for 5 minutes and then washed three times in 
23 
PBS. Tissue sections were kept in a moist chamber for im-
munofluorescence processing. 
rmmunofluorescence Staining of Tissues 
Tissues were examined for localization of antibody binding by 
indirect immunofluorescence (Johnson, Holbrow, and Dorling, 1978). 
Tissue sections were treated by direct application of ascites, sera, 
euglobulin fraction or isolated monoclonal antibody (IIF4, NMS, TEPC 
183 [IgM}; anti collagen IV mAb, MOPC 21 [IgGl}) at 10 ug, 5 ug, and 
2. 5 ug per section in 1 % BSA for one hour at RT. After three 5 
minute PBS washings, the appropriate conjugate antibody [fluorescein 
conjugated goat anti-mouse IgM, fluorescein-conjugated goat anti-
mouse immunoglobulins; both at 10 ug Ig/ml (HyClone, Logan, UT)} in 
0.1% BSA was applied to the sections for one hour at RT. After 
washing, cover slips were placed on the slides with buffered glycine 
containing ortho-phenylenediamine as a fluorescence quencher 
(Johnson and de Nogueira Araujo, 1981). Sections were viewed with a 
fluorescent microscope (Leitz, Midland, Ontario, Canada). 
Photography of Immunofluorescently Stained Tissue 
Photographs were taken of immunofluorescently stained tissue 
sections with the camera attachment on the Leitz microscope. Black 
and white film (Tri-X Pan,Kodak, Rochester, NY) and color slide film 
(Ektachrome, Kodak) (each at ASA 400) were exposed for 30 seconds. 
Black and white negatives were developed in Microdol (Kodak) diluted 
1:2 for 10 minutes at 20°c, washed, fixed (Kodak fixer) for 15 
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minutes at 20°c, washed and air-dried. Prints were made on F4 paper 
(Kodak), developed in Dektol (Kodak) at 1:2 at 20°c for 1 minute, 
washed, fixed (Kodak fixer) for 10 minutes, washed and air dried. 
Growth of GS-~ Streptococcus mutans 
§. mutans (GS-5) (provided by Dr. Brian Shearer, Department 
of Microbiology, LUMC) 50 ml feeder cultures were grown in 
sterilized tryptic soy broth (TSB, BBL, Beckton-Dickinson, 
Cockseyville, MD) with 2.5 mg/ml yeast extract (BBL) at 37°c with 
shaking overnight (Stinson et al., 1983). Cultures were shown to 
contain one bacteria type by aliquots streaked on blood agar plates 
(Baxter Scientific Products, McGraw Park, IL) and incubation at 37°c 
for two days. Feeder cultures were added to TSB (2 L) and incubated 
at 37°c with shaking for 6 hours. At this time, 50 ml of filter 
sterilized 5% glucose (Sigma) and 50 ml of sterilized 5% bicarbonate 
(Mallinckrodt, Inc., St. Louis, MO) were added to the cultures to 
boost growth. After 24 hours of incubation, bacteria were collected 
by centrifugation at 4424 x g (J2-21 Centrifuge, Beckman, Oxnard, 
CA) for 10 minutes and washed with PBS-0.05% NaN3 (Sigma) until the 
supernatants read <0.2 O.D. at 278 nm. Bacteria were heat killed at 
a density of 10% in PBS-azide at 80°c for 15 minutes with shaking. 
Total culture killing was checked by aliquots streaked on blood agar 
plates incubated at 37°c for two days. 
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preparation of Group ~ .IYPg 12 Streptococci 
Whole cells of heat killed group A type 12 streptococci 
(previously prepared in this laboratory) were washed repeatedly in 
saline at 17699 x g (Beckman) until the supernatants read <0.2 O.D. 
at 278 run (Model 139, UV-Vis Spectrophotometer, Hitachi Perkin-
Elmer, Danbury, CT). 
Preparation of Bacterial Cell Membrane 
Bacterial cells were disrupted with the BeadBeater cell 
disrupter (Biospec Products, Bartlesville, O.K.) using 0.1 mm 
diameter glass beads previously washed in 50% sulfuric acid and 
several volumes of distilled water. The BeadBeater chamber was one-
third filled with glass beads, bacteria, distilled water and 
surrounded with ice. Two volumes of glass beads to one volume of 
bacteria was used for maximum bacterial breakage. The cells were 
disrupted by a five minute on, five minute off cycle repeated five 
times (Bleiweis, Karakowa and Krause, 1964). Examinations of Gram 
stains and wet mounts under phase contrast confirmed presence 
disrupted cells. Differential centrifugation isolated bacterial 
cell membrane. Centrifugation at 4424 x g for 10 minutes pelleted 
whole cells and some cell wall; centrifugation at 6370 x g for 10 
minutes pelleted cell wall and centrifugation at 34957 x g for 10 
minutes pelleted bacterial membranes. Membrane preparations were 
dialyzed (3000 molecular weight cutoff, Sephraphor, Spectrum Medical 
Industries, Inc., Los Angeles, CA) against distilled water and 
lyophilized (Freezemobile 12, The Virtis Co., Gardiner, NY). 
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The isolation of group A type 12 streptococcal cell membrane 
was carried out by Mark Zelman in this laboratory; his preparations 
are used throughout this study. 
Rhamnose Determination of Cell Membrane 
The procedure of Dische and Shettles (1946) was used to 
determine rhamnose (methyl pentose) level in the membrane 
preparations. A level of <0.1% is acceptable for purified group A 
type 12 streptococcal cell membrane (Markowitz and Lange, 1964). 
4.5 ml chilled 87.5% sulfuric acid was added to ice cold solutions 
of methyl pentose (Mann Research Laboratories, New York, NY) (2.75, 
5.50, 8.25, 10.0 ug/ml) in 1 ml saturated benzoic acid with constant 
shaking in an ice bath. After standing 10 minutes at RT, the tubes 
were placed in boiling water for 3 minutes. After cooling to RT, 
0.1 ml of 3% cysteine hydrochloride monohydrate was added to each 
tube. After two hours at RT, the absorption was read at 396 nm and 
430 run. A blank containing 1 ml saturated benzoic acid, 4. 5 ml 
87. 5\ sulfuric acid and O .1 ml cysteine hydrochloride monohydrate 
was read. The difference in the absorptions (396 run - 430 run) gave 
the rhamnose concentration (ug/ml). The principle of this assay is 
based on the absence of methyl pentose absorbance at 430 run. 
Hexoses, pentoses, glucuronic and galacturonic acids have 
symmetrical absorption curves such that the absorbance at 430 run and 
396 run is the same. Subtraction of the absorbance at 430 run from 
the absorbance at 396 run corrects for all the absorbance except for 
that due to methyl pentose. The membrane and cell wall samples were 
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first digested in 87.5% sulfuric acid by boiling for 3 minutes. The 
percent rhamnose was determined by examining the standard curve and 
assigning a concentration to the unknown. 
% rhamnose = ug rhamnose in sample x 100 
ug membrane in assay. 
Cell membrane prepared from group A type 12 streptococcal 
cell membrane was judged to be free of cell wall contaminants by 
determining the rhamnose concentration of the preparation. The 
trypsin digested SCM was found to have less than 0. 08% rhamnose; 
this is considered free of cell wall contaminants (Markowitz and 
Lange, 1964; Lange, 1980a). 
Cell membrane was isolated from ~- mutans. The yield of ~· 
mutans cell membrane was 0.135 grams. A 9.5 gram wet weight is e-
quivalent to 2-4 grams dry weight of bacteria. Bacterial membrane 
is approximately 10% of the cell. The minimal expected weight of 
isolated membrane is 0.2 grams; the yield of ~- mutans cell membrane 
is approximately 67.5%. 
Trypsin Digestion of Bacterial Cell Membrane 
Lyophilized SCM or ~· mutans cellular membrane was weighed 
and 1 mg trypsin (Sigma) in PBS, pH 6. 0, was added per 100 mg 
membrane preparation (Markowitz and Lange, 1964; Lange, 1969). This 
preparation was rotated at 37°c for 18 hours, centrifuged at 483 x g 
for 10 minutes and the supernatant was dialyzed against distilled 
water overnight at 4°c with a membrane cutoff of 3000 molecular wei-
ght (Sephraphor). The supernatant was concentrated to a small vol-
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ume (Speed-vac, Savant Instruments, Inc., Hickville, NY). The 
concentrated, digested membrane was stored at -20°c until use. 
Isolation of Human Glomeruli 
Glomeruli were isolated as previously described (Greenspon 
and Krakawer, 1950; Markowitz and Lange, 1964; Blue and Lange, 
1975). Human kidneys were weighed and cortical tissue was separated 
from medullary tissue with scissors. Cortices were then forced 
through a 64u mesh screen into a watch glass on ice adding cold PBS 
with 30 uM tannic acid (Aldrich Chemicals, Milwaukee, WI) and the 
nonspecific protease inhibitor, PMSF (phenylmethylsulfonyl fluoride; 
1 nM final concentration, Sigma), as needed to facilitate the proc-
edure. Cortical material was collected from the watch glass and al-
lowed to settle in cold PBS with tannic acid and PMSF and the super-
natant was aspirated. This was repeated six times yielding a rela-
tively pure preparation of whole glomeruli free of other cells and 
debris; this was checked by phase contrast microscopy. Glomerular 
basement membrane was prepared from isolated glomeruli (Carlson 
al., 1978). The glomeruli were then osmotically shocked with dis-
tilled water with 0.05% NaN3 and PMSF overnight at RT with gentle 
shaking to free the glomerular basement membrane (GBM). The prep-
aration was centrifuged for 10 minutes at 483 x g and the 
supernatant was aspirated. 3% Triton-X 100 was added and the tubes 
were rotated for 2-4 hours. The preparation was centrifuged as 
above and the pellet treated with 2000 units of DNase in 1 M NaCl 
and gently shaken and incubated for 1-2 hours at 37°c. The prepara-
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tion was centrifuged and the pellet treated with 4% deoxycholate for 
2 hours at RT. After centrifugation, the pelleted material was 
washed 5 times in azide-water. The recovered sediment was judged by 
microscopic review to be >95% purified glomerular basement membrane 
and was stored at -20°c until digestion. This procedure yields a 
preparation that is enriched· for glomerular basement membrane. 
Enzyme Digestion of Human GBM or Collagen 
Enzymatic digestions of membrane preparations were 
essentially as previously described (Markowitz and Lange, 1964; 
Lange, 1969). Some modifications are as follows. 
Glomerular basement membrane (GBM) sediment, collagen type I 
(Sigma) or collagen type IV (Sigma) was weighed and 1 mg bacterial 
collagenase (Sigma) in PBS, pH 7.4, with 0.01 mM calcium lactate and 
1 mM PMSF was added per 100 mg of GBM sediment or collagen. 
Preparations were rotated slowly for 18 hours at 37°c and then 
centrifuged at 483 x g for 30 minutes. Supernatants were stored at 
-20°c until use. 
Glomerular basement membrane, collagen I, or collagen IV was 
weighed and 1 mg of trypsin (Sigma) in PBS, pH 6.0, was added per 
100 mg sediment or protein. Preparation were rotated for 18 hours 
at 37°c and then centrifuged at 483 x g for 10 minutes. 
natants were stored at -20°c until use. 
Super-
GBM, collagen I, or collagen IV were pepsin digested (Qian 
and Glanville, 1984; Glanville et al., 1985). GBM sediment (GBM 
18509 N, 18274 N) or protein was digested by adding 0.02 milligrams 
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of pepsin (Nutritional Biochemicals Corporation, Cleveland, OH) per 
milligram of material to be digested in 0.5 M formic acid (pH 2.0) 
at 4°c with mixing for 16 hours. After neutralization with 10 N 
NaOH, the mixture was centrifuged and stored at -20°c until use. 
Amino Acid Analysis 
Protein, isolated polypeptide or whole collagenase or trypsin 
digested glomerular basement membrane was digested to single amino 
acids with constant boiling 5.7 N HCl in sealed N2 flushed, 
evacuated tubes for 22 hours. Preparations were dried a desiccator 
containing NaOH pellets which absorb HCl from the sample. Dried 
preparations were dissolved in sample buffer and analyzed (Beckman 
6300 Amino Acid Analyzer) using an ion exchange column and lithium 
buffers and a program that compares amino acid composition of the 
preparation to a standard separation of amino acids. Amino acid 
composition was converted to percent amino acid per 100 amino acid 
and total weight (microgram) of preparation using a spreadsheet 
(Lotus 1-2-3, Cambridge, MA). 
Enzyme Linked Immunosorbant Assay (ELISA) 
Proteins, polypeptides, or tissue isolates were tested for 
reactivity to anti-SCM mAb by ELISA (Voller, Bidwell and Bartlett, 
1980). Plates ( 96 wells) were sensitized with 5 ug/ml of the 
material to be assayed in 0.05 M carbonate buffer, pH 9.6, overnight 
at RT. Wells were blocked with 1% BSA in PBS for two hours at RT. 
Dilutions of a known antibody concentration of mAb, serum or ascites 
were applied to the plates for one to two hours at RT. 
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For IgM 
primary antibody,dilutions of 20 ug/ml to 0.078 ug/ml (100 ul/well) 
were applied to the plates in triplicate. For IgGl primary an-
tibody, dilutions of 45 ug/ml to 0.01 ug/ml were applied to the 
plates. After extensive washing with PBS-0.05% Tween 20, enzyme 
conjugated detector antibody was added to the wells ( 100 ul/well) 
for one hour at RT. A peroxidase-labeled goat anti-mouse IgM 
antibody (HyClone, Logan, UT) and a peroxidase labeled goat anti-
mouse IgG antibody (HyClone) were used at 0.1 ug/ml in 1% BSA-PBS 
for IgM and IgGl primary antibodies, respectively. After extensive 
washing, substrate was applied to the wells (150 ul/well) and 
allowed to develop for 30 minutes and then read with a microplate 
reader at 405 nm. For peroxidase conjugated detector antibody, 
equal parts of 0.02% 2,2'-azinodi-(3-ethylbenzthiazoline sulfonic 
acid) {Sigma) in 0.1 M citrate buffer, pH 4.1 and 0.01% H202 in PBS 
were used as substrate. Absorption was read at 405 nm at 30 
minutes. Mean optical density and standard deviation were 
calculated for each reading and plotted versus ug/ml of antibody. 
Competitive Inhibition Studies of IIF4 Reactivity 
a. Streptococcal cell membranes .!!.§. competitors 
Dilutions of trypsin digested SCM or trypsin digested §.. 
mutans cell membrane {final concentration: 40 ug/ml to 0.1 ug/ml) 
were added with IIF4 (final concentration: 2.5 ug/ml) in PBS and 
incubated at 37°c for two hours. After centrifugation,, 100 ul/well 
was applied to a trypsin digested SCM (0.5 ug/ml) sensitized and BSA 
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blocked 96 well plate. After a one hour incubation and extensive 
washing with PBS-0.05% Tween 20, plates were processed as described 
in ELISA and tested for unbound antibody on plates sensitized with 
trypsin digested SCM or pepsin digested collagen IV. These assays 
were performed with at least three replicates and each experiment 
was performed at least three times. 
~· Fibronectin, heparan sulfate proteoglycan, laminin, and bovine 
~ albumin as competitors 
Laminin, and heparan sulfate proteoglycan are major 
components of GBM along with collagen IV. Native fibronectin (human 
serum; Boehringer Mannheim, Indianapolis, IN), native laminin 
(derived from Englebreth-Holm-Swarm Mouse sarcoma; Sigma, St. Louis, 
MO.), heparan sulfate proteoglycan (derived from bovine kidney; 
Sigma) and bovine serum albumin (Sigma) were diluted in PBS (final 
concentrations, 1.0 to 0.00001 ug/ml) were incubated with IIF4 
(final concentrations, 2. 5 ug/ml) at 37°c for two hours and then 
processed as above. 
~· Enzyme digests of collagen !, collagen IV, and GBM .9..2 competitors 
This assay was used to determine IIF4 reactivity with the 
major constituent of GBM, collagen IV, and as a comparison, collagen 
I and with GBM. Dilutions of collagenase digests of GBM and human 
placenta collagen IV (Sigma) and pepsin digests of human placenta 
collagens I and IV (final concentration,10 to 0.0001 ug/ml) were 
33 
incubated with IIF4 (final concentration, 2.5 ug/ml) at 37°c for two 
hours and then processed as described above. 
competitive Inhibition of anti-collagen IV mAb reactivity 
As a comparison for competitive inhibition of IIF4 
reactivity, the anti-collagen IV mAb reactivity was competitively 
inhibited by pepsin digested human placenta collagens I and IV, 
fibronectin, and trypsin digested SCM. Dilutions of SCM, pepsin 
digested collagens I and IV and fibronectin (final concentration, 10 
to 0.00001 ug/ml) were incubated with anti-collagen IV mAb (final 
concentration, 0.5 ug/ml) for two hours at 37°c and then processed 
as described in ELISA except that the antibody-inhibitor mixture was 
applied to 96 well plates sensitized with trypsin digested GBM at 
0.5 ug/well and peroxidase labeled goat anti-mouse IgG at 0.1 ug/ml 
was used as the secondary antibody. 
SOS-PAGE of Proteins 
Bacterial membrane preparations, glomerular basement membrane 
preparations, isolated proteins, or immunoprecipitated complexes 
were separated on sodium dodecyl sulfate polyacrylamide elec-
trophoresis (SOS-PAGE) (Lammeli, 1970). A 10% or 15% gel ( 10% or 
15% acrylamide, 1% N-N methylene bis-acrylamide crosslinker, Kodak) 
was polymerized using ammonium persulfate ( 1. 7 mM final 
concentration) and TEMED (0. 52 mM final concentration) (Sigma). 
Stacking gels of 5% were used. Proteins to be applied to gels were 
denatured by incubating at 90°c for 5 minutes in sos-sample buffer 
(0.06 M Tris, 10% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol·, 2.3% 
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SOS / pH 6 • 8 ) • Proteins of known molecular weight were used as 
standards (Bio-Rad, Richmond, CA.): phosphorylase B, 97.4 kDa; 
bovine serum albumin, 66.2 kDa; ovalbumin, 42. 7 kDa; carbonic an-
hydrase, 31.0 kDa; soybean trypsin inhibitor, 21.5 kDa; lysozyme, 
14.4 kDa. Proteins were electrophoresed through the stacking gel at 
70 V and through the separating gel at 175 V. The runs were ter-
minated when the bromophenol blue dye (1% aqueous) included in the 
standard molecular weight protein mixture reached the bottom of the 
gel. 
Staining of and Duplicating Protein Gels 
Gels were stained with Coomassie Brilliant Blue R-250 or were 
silver stained (described below). Gels were stained in 10% 
Coomassie Brilliant Blue R-250 (Sigma) in 50% trichloroacetic acid 
(Sigma) for 1-2 hours with agitation. Gels were destained in 7.5% 
acetic acid and 5% methanol for several hours. Coomassie stained 
gels were duplicated by positive photographic images with EDP 
Electrophoresis Duplicating Paper (Kodak). Under a lA red safelight 
filter, EDP paper was placed emulsion side up on a flat surface. An 
amber filter (supplied by the manufacturer) was placed between the 
EDP paper and the gel to be duplicated. A 15-watt incandescent 
light source was placed 36 inches over the EDP paper/filter/gel 
assembly and the paper was exposed for 15-20 seconds. EDP paper was 
developed in Dektol at 1: 1 for 2 minutes at RT, washed and then 
fixed (Kodak fixer) for 2 minutes at RT, washed for 2 minutes and 
then air dried. 
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KJ..ution of Protein from SOS-PAGE 
Protein preparations containing higher molecular weight 
proteins (100-140 kOa) of interest were separated on 6.5\ SOS-PAGE, 
stained with Coomassie Brilliant Blue and destained. Stained bands 
of interest with cut from the gel and minced into small ( 1 mm3) 
pieces. Gel pieces were washed in. distilled water and then 
equilibrated in 0.05 M NH4co3, 0.1\ SDS for 2 hours at RT. After 
equilibration, gel pieces were placed on the cathode side of a 
lucite chamber; chamber halves were separated by a dialysis membrane 
(3000 MW cutoff, Sephraphor). The lucite chamber was cooled at all 
times in an ice bath to prevent overheating of the gel pieces. 
After 50 milliamperes were applied for approximately two hours, 
supernatant was recovered from both halves of the chamber, dialyzed 
against 20% methanol overnight at 4°c, dialyzed against distilled 
water for 2 hours at 4°c, and lyophilized. Protein in eluted 
material was quantitated and then subjected to amino acid analysis. 
Recovery of protein from SDS-PAGE, elution and dialysis was poor, in 
the range of 15-20\. This was determined by comparing the density 
of the polypeptide band to the total density of the total protein in 
the lane. 
Immunoprecipitation 
In order to specifically detect proteins or polypeptides 
reactive with anti-SCM mAb, immunoprecipitation was done (Chen 
al., 1986; Weir, 1979). Immunoprecipitation of proteins reactive 
with anti-SCM mAb was carried out using goat anti-mouse IgM ·coupled 
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to agarose beads (Sigma). The beads will bind a maximum of 0.4 mg 
IgM per ml of bead. The agarose beads were washed extensively with 
PBS. GBM, SCM, or other protein aliquots were pre incubated by 
treatment with pre-washed beads for one hour with mixing at 37°c. 
The SCM, GBM or other protein aliquots were recovered by 
centrifugation. To couple ·mAb to the beads, either anti-SCM mAb, 
IIF4, TEPC 183, or IgM from the euglobulin fraction of normal mouse 
serum was reacted with the pre-washed beads at 0.5 mg/ml for 18 
hours at 4°c with gentle mixing. The beads are then washed four 
times in 4 volumes of cold PBS to remove unbound mAb. Protein to be 
precipitated (SCM, GBM or other protein) was added to the bead/mAb 
complex at 1 mg/ml (100 ug total) and incubated at 4°c for 18 hours 
with gentle mixing. After three washings in four volumes of PBS, 
precipitated material was eluted from the beads with 0 .1 acetic 
acid, 0 .15 M NaCl, pH 2. 4 for 3-5 minutes with gentle mixing. 
Eluted material was recovered by centrifugation, neutralized with 10 
N NaOH, dialyzed against distilled water for 15 minutes and 
concentrated to a small volume (approximately 30 ul). Eluted mater-
ial was then denatured in SOS sample buffer and applied to 10% or 
15% SOS-PAGE. After electrophoresis, gels were silver stained. 
Preclearing of Immunoprecipitable Material 
In order to demonstrate specificity of the 
immunoprecipitation reaction, a preclearing step was added to the 
above protocol. Protein that was preincubated with the agarose 
beads was subjected to immunoprecipitation as described above with 
37 
IIF4 or TEPC 183 conjugated beads. The supernatant of the 
immunoprecipitation reaction was reacted again with fresh IIF4- or 
TEPC 183-conjugated beads. Material was eluted and processed as 
described in the immunoprecipitation section. 
silver staining of SOS-PAGE 
Gels were silver stained in order to detect small amounts of 
protein (Gooderham, 1984). After electrophoresis, gels were pre-
fixed in 50% methanol overnight. Gels were fixed in 10% 
glutaraldehyde for 30 minutes with agitation. Gels were washed free 
of excess glutaraldehyde with four distilled water washes of 30 
minutes each. Gels were treated with ammoniacal silver. 8.0 ml of 
0. 07 3 mM AgN03 was added to a solution of 93% 0 .1 N NaOH and 7% 
NH40H ( 45 ml total). This was the diluted to 200 ml (total) an 
added to a gel for 20 minutes with rocking, washed twice with 
distilled water and then developed (0.1 grams of citric acid, 0.1 ml 
of 37% formaldehyde in 200 ml distilled water) for 20 minutes. Gels 
were held in 50% methanol until photographed. 
RESULTS 
Anti-SCM mAb is IgM Isotype 
After production of murine monoclonal antibodies to group A 
type 12 SCM (Fitzsimons, Weber and Lange, 1987), one of the mAbs was 
isotyped. As positive controls, a 1:500 dilution of normal mouse 
serum, 0.5 ug/ml each of murine myeloma TEPC 183 mAb (IgM), murine 
myeloma MOPC 21 mAb (IgGl), and anti-collagen IV mAb (IgGl) were 
used. The isotypes of TEPC 183, MOPC 12 and anti-collagen IV were 
previously known from the supplier and were used as monoclonal 
controls for the isotyping system. As demonstrated in Table 1, all 
mAbs with previously known isotypes reacted as expected; normal 
mouse serum contains all isotypes and all isotypes were detected. As 
a negative control, a 1: 500 dilution of normal rabbit serum was 
used; since this is a murine isotyping system, no murine isotypes 
were detected in normal rabbit serum. The anti-SCM mAb, IIF4, was 
isotyped as IgM. 
Reactivity of IIF4 with SCM and ~. mutans Cell Membrane 
This experiment was performed to demonstrate the reactivity 
of anti-SCM mAb, IIF4, with its autologous antigen, group A type 12 
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TABLE 1. 
Isotype of Murine Monoclonal Antibodies 
Monoclonal Isotype 
Anti-collagen IV IgGl 
MOPC 21 IgGl 
TEPC 183 IgM 
IIF4 IgM 
Control sera 
normal mouse serum + all isotypes 
normal rabbit serum - all isotypes 
All monoclonal antibodies were tested at 0.5 ug/ml; sera were 
tested at a dilution of 1:500. 
Euglobulin fraction of ascites IIF4 was tested. 
A positive isotype was an optical density > 0.600 at 405 nm. 
Isotypes of anti-collagen IV mAb, TEPC 183, and MOPC 21 were 
previously known and used as controls. 
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scM and compare this reactivity to §. mutans cell membrane. In an 
ELISA, O. 5 ug of either trypsin digested SCM or §. mutans cell 
membrane were reacted with equal amounts of IgM in IIF4, TEPC 183, 
or normal mouse serum (5 ug/ml to 0.313 ug/ml). In Figure 1, IIF4 
reacted with SCM and not another streptococcal cell membrane, §. 
mu tans membrane (at 5. 0 and 2. 5 ug/ml IIF4, p < 0. 001) • TEPC 183 
and IgM from normal mouse serum did not react with SCM (at 5.0 and 
2.s ug/ml IgM, p < 0.001). Reactions of IIF4 and TEPC 183 with the 
cell membrane from §. mutans were not statistically different (at 
5.0 and 2.5 ug/ml IgM, p>0.05). This result indicates that anti-
group A type 12 SCM mAb reacted with its autologous antigen, group A 
type 12 SCM. §. mutans cell membrane will be used as a negative 
control for SCM. 
Competitive Inhibition of IIF4 Reactivity with SCM and §. mutans 
Cell Membrane as Inhibitors 
IIF4 reactivity, as presented in Figure 1, with its 
autologous antigen, SCM and not with another streptococcal cell 
membrane from §. mutans was confirmed by competitive inhibition. 
Trypsin digested SCM, at 5000 ng, inhibited IIF4 reactivity 
to a maximum of 50%. Trypsin digested cell membrane from §. mutans 
did not inhibit IIF4 reactivity t6 any extent distinguishable from 
background (Figure 2). This result confirmed and demonstrated that 
IIF4 reacted with its autologous antigen, SCM, and not another 
streptococcal cell membrane from §. mutans. 
£igure £. Reactivity of IIF4 with Trypsin Digested Group A ~ 12 
scM and Trypsin Digested Cell Membrane from §. mutans 
IIF4, TEPC 183 and IgM from NMS (serial dilutions of 5.0 to 0.313 
ug/ml IgM) were applied to 96 well plates sensitized with 5.0 ug/ml 
of either trypsin digested SCM or trypsin digested §. mutans cell 
membrane. After application of peroxidase labeled goat anti-mouse 
IgM at O.l ug/ml and peroxidase based substrate, color development 
was recorded at 405 nm at 30 minutes. 
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Figure £. Competitive Inhibition of IIF4 Reactivity with Bacterial 
Cell Membranes 
IIF4 reactivity with trypsin digested SCM (5.0 ug/ml bound to a 96 
well plate) was competitively inhibited with trypsin digested SCM, 
but not trypsin digested ~. mutans cell membrane. IIF4 (2.5 ug/ml) 
was reacted with dilutions of SCM or ~· mutans cell membrane for two 
hours at 37°c. Aliquots (100 ul/well) were then applied to trypsin 
digested SCM plates. After processing as described in METHODS, 
color development was recorded at 405 nm at 30 minutes. Each assay 
was preformed a minimum of three times with a minimum of three 
replicates for each point and the average and standard deviation of 
IIF4 reactivity is presented. 
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Anti-SCM mAb Binding is Localized to GBM 
IIF4 was hypothesized to recognize an epitope in human GBM. 
cortical tissue from human kidneys (18274 N, 19442 N, 19226 N, 19763 
N) was assayed for binding of anti-SCM mAbs. Cortical tissue 
treated with TEPC 183 showed no binding of antibody on indirect im-
munofluorescence. However, equal amounts of anti-SCM mAb IIF4 
showed immunofluorescence of GBM in the cortical tissue preparations 
examined (Figure 3). A granular pattern of immunofluorescence was 
consistently seen in all cortical tissue examined. Nuclei of 
mesangial cells were autofluorescent (yellow-orange in color). Some 
immunofluorescent staining was also seen of tubular basement membr-
ane, mesangial matrix, and vessel walls. 
Analysis of 25 GBMs 
Twenty five human GBMs were analyzed for amino acid 
composition. In Table 2, the compiled percentage of each amino acid 
in the GBMs is given. The presence of hydroxyproline and 
hydroxylysine in the 25 GBMs established these GBMs as containing 
collagen; only collagen contains these amino acids. 
Reactivity of Anti-SCM mAb with Isolated Human Glomerular Basement 
Membrane (GBM) 
IIF4 was hypothesized to react with isolated, human GBM. To 
test this, GBMs were isolated as described from 26 human kidneys. 
5 ug of isolated, solubilized GBMs were individually coated 
Figure J. Indirect Immunofluorescence of Human Renal Cortical Tissue 
with IIF4 and TEPC 183 
cryostat sectioned human renal cortical tissue was treated with IIF4 
or TEPC 183 ( 10 ug of IgM in 1% BSA) for one hour at RT. After 
washing, tissue sections were incubated with fluorescein-conjugated 
goat anti-mouse IgM for one hour at RT, washed and viewed on a 
fluorescent microscope. Panel A is IIF4 treated cortical tissue; 
IIF4 bound to GBM in a granular pattern, mesangial matrix, and 
tubular basement membrane. TEPC 183 (Panel B) did not bind to the 
cortical tissue. Mesangial nuclei were auto-fluorescent. 
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TABLE 2. 
Amino Acid Composition of 
Human Glomerular Basement Membrane 
(percent amino acid) 
Percent Amino Acid 
Amino Acid (mean +/- SD) 
Cysteic acid 0.98 +/- 0.99 
Aspartic acid 8.86 +/- 0.48 
Hydroxyproline 3.62 +L- 1.32 
Methionine sulfoxide 0.57 +/- 0.31 
Threonine 4.53 +/- 0.58 
Serine 4.32 +/- 0.52 
Glutamic acid 12.73 +/- 0.84 
Pro line 6.85 +/- 0.61 
Glycine 13.57 +L- 2.50 
Alanine 4.70 +/- 0.41 
Hexosamines 0.16 +/- 0.15 
Valine 4.66 +/- 0.76 
Cysteine 0.45 +/- 0.37 
Methionine 0.84 +/- 0.41 
Isoleucine 4.04 +/- 0.42 
Leucine 7.85 +/- 0.85 
Tyrosine 3.27 +/- 0.46 
Phenylalanine 4.25 +/- 0.19 
Hydroxy lysine 2.43 +L- o. 72 
Lysine 4.47 +/- 0.60 
Histidine 2.20 +/- 0.26 
Arginine 4.76 +/- 0.85 
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Twenty five human, isolated GBMs were analyzed for amino acid 
content. Each GBM was analyzed twice. The mean is the mean of the 
means for the 25 samples for each amino acid. 
SD-- standard deviation. 
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on 96 well plates and reacted with IIF4 and TEPC 183. In Figure 4, 
the individual results of 26 GBMs reactivity with IIF4 and TEPC 183 
at 5.0 ug/ml IgM are compiled and shown. As represented in this 
paired data, all GBMs reacted with to a greater extent with IIF4 
than TEPC 183 (p<0.01, at minimum significant difference). The GBM 
with the least difference in reactivity between the levels of IIF4 
and TEPC 183 reactivity displayed significantly greater reactivity 
with IIF4 (at 5.0 and 2.5 ug/ml IgM, p<0.02, in both cases). At 5.0 
ug/ml IgM, the mean of the means of the GBMs for IIF4 reactivity was 
significantly greater than the mean of the means for TEPC 183 (at 
p<0.001). These data indicated that all of the GBMs reacted 
preferentially with IIF4 as compared to TEPC 183. These data further 
indicated that IIF4 reacted with isolated human GBM and reacted with 
all GBMs tested. 
IIF4 Reactivity with Trypsin or Collagenase Digested GBMs 
Since IIF4 was shown to react with isolated GBMs, reactions 
of IIF4 with trypsin digested GBMs and collagenase digested GBMs 
were examined. IIF4 reacted to an equal extent with trypsin 
digested GBMs and collagenase digested GBMs (Figure 5). In this 
paired data, the mean of the means at 5.0 ug/ml IIF4 indicated no 
difference in IIF4 reactivity to the two types of enzyme digested 
GBMs (p>0.2 for trypsin versus collagenase digested GBMs). TEPC 183 
reactivity with trypsin digested GBMs was less than with collagenase 
digested GBMs; reactions of TEPC 183 with collagenase digested GBMs 
Figure ~· IIF4 Reactivity with 26 Human GBMs 
Isolated, trypsin digested or collagenase digested human GBMs were 
reacted with IIF4 and TEPC 183 in ELISA. Plates were sensitized 
with 5.0 ug/ml of the GBM and reacted with IIF4 or TEPC 183 (10 to 
0. 05 ug/ml IgM) for one hour at RT. After washing, plates were 
processed as described in METHODS and MATERIALS. Each GBM was 
assayed in triplicate at least three times. Reactivity of the GBMs 
at 5.0 ug/ml of IIF4 and TEPC 183 is shown as paired data. 
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Figure ~- IIF4 does not React Differently to Trypsin and Collagenase 
Digested GBMs 
IIF4 reactivity of trypsin versus collagenase digests of GBM was ex-
amined at 5.0 ug/ml of IIF4 and TEPC 183. Reactions of TEPC 183 
with trypsin digested and with collagenase digested GBMs are also 
shown. 
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Figure ~- Bimodal Distribution of IIF4 Reactivity with 26 GBMs 
IIF4 reactivities at 5.0 ug/ml with the GBMs were placed in optical 
density groups of 0.05 and plotted for frequency of occurrence 
without regard to standard error. There are two groups of GBM with 
respect to extent of IIF4 reactivity when reactivity is examined in 
this manner. 
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were greater than with trypsin digested GBMs, but reactivity of TEPC 
183 with collagenase digested GBMs is significantly less than IIF4 
reactivity with collagenase digested GBMs (at 5.0 ug/ml IgM, 
p<0.05). However, the range of TEPC 183 reactivity with trypsin 
digested GBMs was encompassed by the range of TEPC 183 reactivity 
with collagenase digested GBMs. These results indicate that TEPC 
183 reactivity in this system was variable and was considered 
nonspecific. These results demonstrated that IIF4 reacted equally 
well with trypsin and collagenase digested GBMs; this strongly 
suggested that the IIF4 epitope exists in both types of enzyme 
digested GBM preparations. 
Bimodal Distribution of Reactivity with 
Values for IIF4 reactivity at 5. 0 ug/ml IgM with 26 human 
trypsin or collagenase digested GBMs were placed in 0.05 o.o. groups 
and plotted for frequency occurrence without regard to standard 
error of the reactivity of each GBM with IIF4. As shown in Figure 
6, two groups of GBMs were evident. These data suggested that two 
groups of GBM, one with higher IIF4 reactivity and one with lower 
IIF4 reactivity, existed in the population of 26 GBMs examined. 
Comparison of IIF4 Reactivity among Bacterial Cell Membranes, 
Isolated Proteins Comprising GBM, and GBM 
Anti-SCM mAb, IIF4, was hypothesized to recognize an epitope 
common to SCM and GBM. It is useful to compare IIF4 reactivity with 
SCM, proteins comprising the GBM and the GBM itself so that one may 
57 
begin to understand how IIF4 reacts with preparations thought to 
contain the common epitope. Figure 7 compares IIF4 reactivity among 
these protein preparations. 
Figure 7, panel A represents data in which trypsin digested 
SCM reacted to a significantly greater extent than trypsin digested 
~- mutans cell membrane (at 5.0 and 2.5 ug/ml IgM, p<0.001) (Figure 
1). In Panel B, IIF4 and TEPC 183 reactivity among collagenase, 
trypsin, or pepsin digests of GBMs is represented. In this sample of 
IIF4 reactivity with enzyme digested GBMs, all GBM preparations 
reacted with IIF4 to a similar extent; these results are examined in 
more depth in Figure 8. All enzyme digested GBMs reacted with IIF4 
to a significantly greater extent than with TEPC 183 (for each 
preparation, at 5.0 and 2.5 ug/ml IgM, p<0.01, at minimum 
significant difference). 
Panel C represents IIF4 reactivity with collagenase digested 
collagen I and collagenase digested collagen IV, and native laminin. 
IIF4 did not react with laminin to any extent significantly 
different from TEPC 183 reactivity with laminin (at all antibody 
concentrations, p>0.2). However, collagenase digested collagen I 
and collagenase digested collagen IV did react with IIF4 to a 
significantly greater extent than with TEPC 183 (for both 
preparations, at all antibody concentrations, p<0.001). 
Panel D represents IIF4 reactivity with pepsin digested 
collagen I or collagen IV, trypsin digested collagen I and native 
fibronectin. IIF4 did not react with fibronectin to any extent 
greater than with TEPC 183 (at 5.0 and 2.5 ug/ml IgM, p>0.05). IIF4 
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did react with pepsin digested collagen I and pepsin digested 
collagen IV to a significantly greater extent than the digests did 
with TEPC 183 (at 5.0 and 2.5 ug/ml IgM, p<0.01, at minimum 
significant difference). Trypsin digested collagen I also reacted 
with I IF4 to a greater extent than with TEPC 183 (at 5. O and 2. 5 
ug/ml, p<O.l). The reactivity of collagen I with IIF4 was re-
evaluated in competitive inhibition studies (Figure 8). These 
results indicated that a collagen compound contained the epitope 
reactive with IIF4; this epitope was not part of laminin or 
fibronectin. 
Conformation of IIF4 Reactivity with Collagen IV 
The experiments indicated that collagen IV contained the 
epitope recognized by IIF4; to confirm this result, IIF4 was 
competitively inhibited by isolated components of GBM (Figure 8). 
a. IIF4 Reactivity is not Inhibited f!.:l Laminin, Fibronectin, Heparan 
Sulfate Proteoglycan, or Bovine Serum Albumin 
IIF4 (2.5 ug/ml) was reacted with proteins (100 to 0.01 
ug/ml). Unbound IIF4 antibody was assayed for by applying the IIF4 
protein reaction mixture to trypsin digested SCM plates. The lower 
panel of Figure 8 represents IIF4 reactivity not inhibited by 
laminin, fibronectin, heparan sulfate proteoglycan and bovine serum 
albumin; none of these proteins was able to inhibit IIF4 reactivity 
to any extent distinguishable from no or very low levels of antibody 
inhibition. Bovine serum albumin was included as a globular protein 
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not part of the GBM. These results confirm the ELISA data 
previously presented; IIF4 did not react with GBM components 
fibronectin, laminin, heparan sulfate proteoglycan. 
~· IIF4 Reactivity is Inhibited .Q.y Collagen IV 
IIF4 was reacted with GBM and collagen preparations and 
unbound antibody was assayed as described. The upper panel of 
Figure 8 represents IIF4 reactivity inhibited by enzyme digested 
GBMs and enzyme digested collagen I and IV. Pepsin digested collagen 
I did not inhibit lIF4 reactivity with SCM to any extent 
distinguishable from no or very low levels of IIF4 reactivity 
inhibition. Trypsin digested, collagenase digested, or pepsin 
digested GBMs inhibited IIF4 reactivity to maxima of 52%, 40%, and 
63%, respectively. These results confirmed the IIF4 reactivity with 
trypsin, collagenase, or pepsin digested GBMs as indicated in Figure 
7. Results presented in Figure 8 also confirmed that collagen IV 
contained the epitope recognized by IIF4. IIF4 was inhibited to 
maxima of 73% and 43% by pepsin digested collagen IV and collagenase 
digested collagen IV, respectively. These results confirmed that 
collagen IV, and not other GBM components and not collagen I, 
contains the IIF4 reactive epitope. A level of 40% IIF4 inhibition 
was chosen to include the reproducible 40% inhibition of IIF4 
reactivity by collagenase digested GBM. Amounts of GBM preparations 
and collagen IV preparations required to inhibit 40% of IIF4 
reactivity are summarized in Table 3. 
Figure ]... Comparison of IIF4 Reactivity with Streptococcal Cell 
Membranes, Isolated Components of GBM, and GBM 
This figure is a compilation of IIF4 reactivity versus bacterial 
cell membrane components, isolated GBM components and enzyme 
digested GBMs. All assays were performed with 96 well plates coated 
with 0.5 ug/ml of the appropriate protein. After blocking, plates 
were treated with serial dilutions of IIF4 or TEPC 183 (10.0 to 0.05 
ug/ml IgM in PBS). Plates were processed as described in METHODS 
AND MATERIALS. Each assay was performed a minimum of three times 
and the average reading and standard error is shown. 
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£· IIF4 Reactivity with Pepsin Digested Collagen IV is Inhibited Q.y 
Trypsin Digested SCM and Pepsin Digested Collagen IV 
Competitive inhibition experiments demonstrated that 
collagenase or pepsin digested collagen IV inhibited IIF4 reactivity 
with the IIF4 autologous antigen, SCM. Figure 9 represents 
experiments in which the ability of SCM to inhibit IIF4 reactivity 
with pepsin digested collagen IV was tested. Pepsin digested 
collagen IV inhibited IIF4 reactivity with pepsin digested collagen 
IV to a maximum of 58% while SCM inhibited IIF4 reactivity with 
pepsin digested collagen IV to a maximum of 42%. These results are 
compared for amount of inhibitor required to achieve 40% inhibition 
of IIF4 reactivity (summarized in Table 3). These results further 
show the IIF4 reactive epitope is located in collagen IV. 
~. Summary of IIF4 Inhibition Q.y Bacterial Membranes, GBMS, and GBM 
Components. 
Table 3 represents the compilation of the IIF4 competitive 
inhibition studies presented in Figures 2, 8, and 9. The ability of 
trypsin digested SCM or .§.. mutans cell membrane to inhibit IIF4 
reactivity with SCM to 40% was examined by first-order linear 
regression. It was found that 900 ng of SCM were required to 
achieve this level of IIF4 inhibition; .§.. mutans cell membrane was 
found to be non-inhibitory for IIF4. 
Figure ~. Competitive Inhibition of IIF4 Reactivity with Isolated 
Proteins from the GBM 
Competitive inhibition of IIF4 reactivity was assayed by testing the 
ability of an inhibitor to bind IIF4 and prevent IIF4 from binding 
to a trypsin digested SCM sensitized 96 well plate. The assay is 
described in METHODS and MATERIALS. As represented in the lower 
panel, fibronectin, bovine serum albumin heparan sulfate 
proteoglycan, and laminin are competitively reacted with IIF4. As 
represented in the upper panel, whole enzyme digested GBM 
preparations and enzyme digested collagens are competitively reacted 
with IIF4. These data are summarized in Table 3. 
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Amounts of collagenase, trypsin, or pepsin digested GBMs 
required to achieve 40% inhibition of IIF4 reactivity were 900 ng, 
500 ng, and 1000 ng, respectively. Approximately one-half the 
amount of trypsin digested GBM was required to inhibit IIF4 as 
compared to amounts required of collagenase or pepsin digested GBMs 
to inhibit IIF4. Approximately the same amount of SCM was required 
to inhibit IIF4 as was required of collagenase or pepsin digested 
GBMs. 
Other components of the GBM, fibronectin, laminin, and 
heparan sulfate proteoglycan, were found to be non-reactive with 
IIF4. Bovine serum albumin was also non-inhibitory for IIF4. 
Contrary to data presented in Figure 7, pepsin digested collagen I 
was found to be non-inhibitory for IIF4 in these competitive 
inhibition studies. 
Amounts of pepsin digested collagen IV and collagenase 
digested collagen IV required to achieve 40% inhibition of IIF4 
reactivity with SCM were 300 ng and 1050 ng, respectively. The 
amount of pepsin digested collagen IV required to achieve 40% 
inhibition of IIF4 was one-third the amounts required of SCM, 
collagenase digested GBM and pepsin digested GBM. 
The ability of SCM, §.. mutans cell membrane, and pepsin 
digested collagen IV to inhibit IIF4 reactivity with pepsin digested 
collagen IV was also compared for 40% inhibition of IIF4 reactivity 
and are summarized in Table 3. §.. mutans cell membrane was found to 
be non-reactive with IIF4 while 2000 ng and 200 ng of SCM and pepsin 
digested collagen IV, respectively, were required to achieve 40% 
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inhibition of IIF4 reactivity. These values are approximately the 
same as required of these inhibitors to inhibit IIF4 reactivity with 
SCM. These results confirm the presence of the IIF4 epitope in 
collagen IV. Pepsin digested collagen IV was the best inhibitor of 
IIF4 reactivity with SCM. 
IIF4 Reactive Polypeptides in Collagen IV and GBM 
Competitive inhibition studies established collagen IV as the 
GBM component containing the IIF4 recognized epitope. Collagen IV is 
a complex molecule consisting of three chains (any combination of 
alpha 1 chains and alpha 2 chains). IIF4 reacted with collagen IV 
and it was hypothesized that the location of the IIF4 reactive 
epitope on collagen IV could be identified. Immunoprecipitation of 
collagen IV and GBM polypeptides from enzyme digests were used to 
test this hypothesis. 
~. Immunoprecipitation of GBM Polypeptides with IIF4 
In order to demonstrate GBM polypeptide reactive with IIF4, 
immunoprecipitation with IIF4 was performed with eight GBMs. IIF4 
immunoprecipitated polypeptides of 120, 100, and 36 kDa from 
collagenase digested GBM 11741 N (Figure 10, lane 3). No GBM 
polypeptides were precipitated with TEPC 183 (lane 5). In 
collagenase digested GBM 7415 N, only the 120 kDa polypeptide was 
IIF4 immunoprecipitated (Figure 11, A) and not with TEPC 183. In 
collagenase digested GBM 19763 N, IIF4 did immunoprecipitated the 
TABLE 3. 
SUMMARY OF COMPETITIVE INHIBITION STUDIES 
Inhibition of IIF4 Reactivity 
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Nanogram amount of inhibitor 
required to achieve 40% 
inhibition of IIF4 reactivity 
(OH A TRYPSIN DIGESTED SCH PLATE) 
Inhibitor (at 250 ng of IIF4) 
Trypsin digested SCM 900 +/- 250 ng 
Trypsin digested .§. mu tans 
cell membrane NI 
Collagenase digested GBM 900 +/- 300 ng 
Trypsin digested GBM 500 +/- 95 ng 
Pepsin digested GBM 1000 +/- 300 ng 
Bovine serum albumin NI 
Human serum fibronectin NI 
Murine lam in in NI 
Bovine kidney heparan sulfate 
proteoglycan NI 
Pepsin digested human placenta 
collagen I NI 
Pepsin digested human placenta 
collagen IV 300 +/- 150 ng 
Collagenase digested human 
placenta collagen IV 1050 +/- 360 ng 
Nanogram amount ofinhibitor 
required to achieve 40% 
inhibition of IIF4 reactivity 
(at 250 ng of IIF4) 
(OH A PEPSIN DIGESTED COLLAGEN IV PLATE) 
Trypsin digested SCM 
Trypsin digested .§. mutans 
cell membrane 
Pepsin digested collagen IV 
2000 +/- 700 ng 
NI 
200 +/- 100 ng 
NI-- not inhibitory at 40% inhibition of IIF4 reactivity. 
Nanogram inhibitory values were determined from a first-
order linear regression plot of each inhibitor and at 40% 
inhibition of IIF4 reactivity. 
polypeptides of 120, 
70 
100, and 39 kDa; TEPC 183 did not 
irnmunoprecipitate any apparent GBM polypeptides (Figure 11, B). In 
two of the GBMs, the 120 and 100 kDa polypeptides were IIF4 
irnmunoprecipitated [collagenase digested GBMs: 11778 N (Figure 12) 
and 9662 N (Figure 13) (Table 4)]. These experiments indicated that 
IIF4 reacted with higher molecular weight collagenase digestion 
products of GBM (120 and/or 100 kDa) and sometimes with a 36-39 kDa 
GBM polypeptide. 
In Figure 14, collagenase digested GBM, 8961 N, was 
irnmunoprecipitated with IIF4. A 120, 100, and 26 kDa GBM 
polypeptide with IIF4 immunoprecipitated (lanes 3 and 4; lane 4 was 
a reaction of one half the amount of GBM in the 
irnmunoprecipitation). This reaction appeared to be specific since 
preclearing of the collagenase digested GBM with IIF4 prior to 
irnmunoprecipitation with IIF4 removed the 120, 100, and 26 kDa GBM 
polypeptides from the reaction mixture (lane 5). TEPC 183 did not 
precipitate any GBM polypeptides and preclearing of the GBM 
preparation with TEPC 183 did not have any effect on the elution 
profile (lanes 6 and 7, respectively). 
For comparison, a pepsin digest of GBM was made and immuno-
precipitated by IIF4. IIF4 irnmunoprecipitated two polypeptides from 
a pepsin digested GBM which were 100 and 85 kDa (Figure 15, lane 3). 
IIF4 precleared these polypeptides (lane 4) and TEPC 183 did not 
immunoprecipitate any polypeptides of pepsin digested GBM. 
results are summarized in Table 4. 
These 
Figure 10. Immunoprecipitation of Collagenase Digested GBM 
Polypeptides with IIF4 
IIF4 bound to goat anti-mouse agarose beads was reacted with 100 ug 
of collagenase digested GBM 11741 N and processed as described in 
METHODS AND MATERIALS. Lane 2 represents the separation profile of 
collagenase digested GBM on 15% SOS-PAGE. Lane 3 is the profile of 
IIF4 immunoprecipitated GBM. Lane 5 represents TEPC 183 
precipitated GBM polypeptides. Lane 4 represents IIF4 
immunoprecipitated alone. The gamma, mu, light, and J chains are as 
labeled. 
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Figure 11. Immunoprecipitation of Polypeptides from Collagenase 
Digested GBMs 7415 N and 19763 N 
Collagenase digested GBMs 7415 N and 19763 N were processed as 
described. In panel A, IIF4 immunoprecipitated GBM 7415 N is 
represented Lane 4 represents TEPC 183 immunoprecipitated GBM 7415 
N. In panel B, IIF4 immunoprecipitated GBM 19763 N is represented 
(lane 7). TEPC 183 precipitated GBM 19763 N is represented in lane 
8. 
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Figure 12. Immunoprecipitation 12.Y. IIF4 of Polypeptides from Col-
lagenase Digested GBM 11778 li 
Collagenase digested GBM was processed as described in Figure 10. 
IIF4 immunoprecipitated collagenase digested GBM 11778 N (lane 3) 
and TEPC 183 immunoprecipitated GBM (lane 4) are represented. IIF4 
immunoprecipitated alone (lane 5), TEPC 183 immunoprecipitated alone 
(lane 6), and goat anti-mouse IgM agarose beads processed alone 
(lane 7) are included as antibody chain mobility references. 
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Figure 13. Immunoprecipitation .Qy IIF4 of Polypeptides from Col-
lagenase Digested GBM 9662 N 
Collagenase digested GBM was processed as described in Figure 10. 
IIF4 immunoprecipitated collagenase digested GBM 9662 N in lane 3 
and TEPC 183 imrnunoprecipitated GBM polypeptides (lane 4) are 
represented. IIF4 immunoprecipitated alone (lane 5), TEPC 183 
immunoprecipitated alone (lane 6), and goat anti-mouse IgM agarose 
beads processed alone (lane 7) are included as antibody chain 
mobility references. 
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Figure 14. Immunoprecipitation of Polypeptides from Collagenase 
Digested GBM 8961 li 
Collagenase digested GBM (100 ug) was IIF4 immunoprecipitated (lane 
3). Collagenase digested GBM (50 ug) was IIF4 immunoprecipitated 
(lane 4). IIF4 precleared GBM digest is represented in lane 5. 
TEPC 183 irnrnunoprecipitated and TEPC 183 precleared of the GBM are 
represented (lanes 6 and 7, respectively). IIF4 immunoprecipitated 
alone (lane 8), TEPC 183 irnrnunoprecipitated alone (lane 9), and goat 
anti-mouse IgM agarose beads processed alone (lane 10) are included 
as antibody chain mobility references. 
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Figure 12_. Immunoprecipitation of Pepsin Digested GBM with IIF4 
Separation of pepsin digested GBM polypeptides is represented in 
lane 1. IIF4 immunoprecipitated pepsin digested GBM is represented 
in lane 3. IIF4 precleared GBM is represented (lane 4). TEPC 183 
precipitated pepsin digested GBM polypeptides is represented (lane 
5) • 
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~. Polypeptides from Collagenase Digested Collagen IV Reactive with 
IIF4 
Collagenase digested co 11 agen IV was subjected to 
irnmunoprecipitation with IIF4 or TEPC 183 (Figure 16). Collagen IV 
polypeptides of 120 and 100 kDa were immunoprecipitated by IIF4. 
~· Polypeptides from Pe::isin Digested Collagen 1. and Collagen IV 
Reactive with IIF4 
IIF4 irnmunoprecipitated polypeptides of 200, 140, and 90 kDa 
pepsin digested collagen IV (Figure 17A, lane 2) and these 
polypeptides were precleared by IIF4 (lane 3). This indicated that 
these polypeptides were specific for IIF4. TEPC 183 did not 
precipitate these polypeptides (lane 4). Preclearing the pepsin 
digested collagen IV with TEPC 183 demonstrated higher molecular 
weight polypeptides (200, 140, and 90 kDa) which corresponded to the 
polypeptides IIF4 irnmunoprecipitated with IIF4 (lane 2). Since TEPC 
183 had not immunoprecipitated these polypeptides (lane 4); this 
result is puzzling and it may not be concluded that IIF4 
specifically irnmunoprecipitated these polypeptides. Laminin was not 
immunoprecipitated by either IIF4 or TEPC 183 (Figure 17B, lanes 6-
10). 
For comparison, pepsin digested collagen I was 
immunoprecipitated by IIF4. Neither IIF4 nor TEPC 183 
immunoprecipitated any pepsin digested collagen I polypeptides 
(Figure l 7B, lanes 2, 4 and 7, 9 respectively) and preclearing 
pepsin digested collagen I with either IIF4 of TEPC 183 had no 
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effect on the elution profile (lanes 3 and 5, respectively). These 
results are summarized in Table 4. 
Amino Acid Analysis of IIF4 Reactive Polypeptides 
In order to characterize IIF4 reactive polypeptides from GBM 
and equivalently sized polypeptides from collagen IV, collagenase 
and pepsin digested collagen IV and GBM (19474N, 19763N) were sepa-
rated on 6. 5% SOS-PAGE. The 120 and 100 kDa polypeptides were 
recovered from the collagenase digests of the GBMs and from collagen 
IV; the 100 kDa polypeptides were recovered from the pepsin 
digestions of the GBM and collagen IV. All recovered polypeptides 
were subjected to amino acid analysis (Figures 18 and 19). The IIF4 
reactive polypeptides from collagenase digested GBM or collagen IV 
( 120 and 100 kDa} were similar in their content of aspartic acid 
(10%), glutamic acid (11\), leucine (8%), and lysine (8%). Each 
polypeptide had collagenous character: glycine (10%), hydroxyproline 
and hydroxylysine (1%). Of particular note is the cysteine residue 
content of 2-4%. The 100 kDa polypeptides from pepsin digested 
collagen IV or GBM were similar in their content of aspartic acid 
(8%), serine (8%), glutamic acid (4%) and leucine (7%). Each 
polypeptide had collagenous character: glycine (17%), hydroxylysine 
and hydroxyproline (l-3%). 
Figure 16. IIF4 Immunoprecipitated Polypeptides from Collagenase 
Digested Collagen IV 
Lane 2 represents IIF4 immunoprecipitated collagenase digested 
collagen IV. Lane 3 represents TEPC 183 immunoprecipitated 
collagenase digested collagen IV. IIF4 immunoprecipitated alone 
(lane 4), TEPC 183 immunoprecipitated alone (lane 5) are included as 
antibody chain mobility references. 
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17A. IIF4 Irnrnunoorecipitation of Pepsin Digested Collagen IV 
The IIF4 immunoprecipitati6n of pepsin digested collagen IV is 
represented. IIF4 irnrnunoprecipitated pepsin digested collagen IV is 
represented in lane 2. IIF4 precleared collagen IV is represented 
in lane 3. TEPC 183 immunoprecipitated and TEPC 183 precleared 
collagen IV are represented in lanes 4 and 5, respectively. IIF4 
immunoprecipitated alone (lane 6), TEPC 183 irnrnunoprecipitated alone 
(lane 7), and goat anti-mouse IgM agarose beads processed alone 
(lane 8) are included as antibody chain mobility references. The 
data represented in Figure 178 was part of the experiment shown 
here. 
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Figure 178. IIF4 did not. Immunoprecipitate any Polypeptides from 
Pepsin Digested Collagen I Q.£ Laminin 
These data are part of the experiment shown in Figure 17A. IIF4 and 
TEPC 183 immunoprecipitated or precleared pepsin digested collagen I 
are represented (lanes 2, 3, 4, and 5). IIF4 or TEPC 183 
immunoprecipitated or precleared laminin is represented (lanes 7, 8, 
9, 10) . IIF4 immunoprecipitated alone (lane 11), TEPC 183 
immunoprecipitated alone (lane 12) and the goat anti-mouse agarose 
beads processed alone (lane 13) are included for antibody chain 
mobility references. 
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SUMMARY OF IMMUNOPRECIPITATIO~ DATA 
Collagenase digested GBMs: 
11741 N 
11778 N 
9662 N 
7415 N 
19763 N 
8961 N 
Pepsin digested GBM1 
Pepsin digested collagen rv2 -200, 
Pepsin digested collagen I 
Collagenase digested collagen IV 
Laminin 
140, 
140, 
kDa polypeptide 
immunoprecipitated 
with IIF4 
120, 100, 37 
120, 100 
120, 100 
120 
120, 100, 40 
120, 100, 
100, 85 
90 
none 
120, 100, 45 
none 
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1 Two aliquots of GBM (18274) were pepsin digested separately and 
subjected to IIF4 or TEPC 183 immunoprecipitation. The data 
presented here and in Figure l 7A is a compilation of these two 
digestions and immunoprecipitations. 
2 IIF4 alone did not imrnunoprecipitate pepsin digested collagen IV 
polypeptides; TEPC 183 also had reactivity with these polypeptides 
(Figure 17A). The data is included here for comparison and 
completeness. 
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Anti-collagen IV mAb Reactivity with GBM 
As seen with IIF4, anti-collagen IV mAb reacted with the GBM 
in human cortical tissue (Figure 20). Anti-collagen IV mAb reacted 
with the GBM in a linear deposition pattern as well as reacting with 
mesangial matrix, tubular basement membrane (not shown in 
photograph) and the Bowman's capsule. MOPC 21 did not react with 
the cortical tissue; yellow-orange autofluorescence of cortical 
nuclei was seen in MOPC 21 staining as it had been in TEPC 183 
staining (Figure 3B). These results demonstrated that anti-collagen 
IV mAb reacted with tissue components known to contain collagen IV. 
Comparison of Anti-Collagen IV mAb Reactivity among Bacterial Cell 
Membranes, Isolated Proteins Comprising the GBM, and GBMs 
Since, as represented in Figures 7, 8, and 9, IIF4 reacted 
with collagen proteins and not laminin or fibronectin, and since 
collagen IV comprises up to 80% of the GBM (Wieslander, 1983), the 
reactivity of the bacterial cell membranes and GBM preparations with 
anti-collagen IV mAb was investigated. This was done to contrast 
anti-collagen IV mAb reactivity with IIF4 reactivity among GBM 
components. 
Trypsin digested SCM and trypsin digested cell membrane from 
~. mutans were reacted with anti-collagen IV mAb and MOPC 21 as a 
control (20 to 2.0 ug/ml IgGl). Both bacterial cell membrane 
preparations did not react above background levels of MOPC 21 
reactivity with anti-collagen IV mAb (Figure 21, A). 
Figure 18. Amino S£!.g profile of polypeptides from collagenase 
digested GBM and collagen IV 
The amino acid quantity from each eluted polypeptide is shown here 
as an average of two determinations for that polypeptide. All 
collagenase digests of the 120 and 100 kDa GBM and collagen IV 
polypeptides had similar amounts of cysteine, aspartic acid, 
threonine, serine, glutamic acid, alanine, isoleucine, leucine, 
tyrosine, lysine, and arginine. All digests contained small amounts 
of hydroxyproline and hydroxylysine. 
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Collogenase digested Human GBM 
polypeptide t 20 kOo 
Collogenose digested collagen IV 
polypeptide t 20 kOa 
Collogenase digested Human GBM 
polypeptide t 00 kOa 
Collagenase digested collagen IV 
polypeptide 100 kDo 
CD~ MTS EP GAJ V LYF~KHR 
Amino Acid 
HOP-hydroxyproline J-hexosomines HOL-hydroxylysine 
Figure 19. Amino acid profile of polypeptides from pepsin digested 
GBM and collagen IV 
Isolated polypeptides from pepsin digested GBM or collagen IV of 100 
kDa had very similar amounts of most amino acids. Each polypeptide 
contained an equivalent amount each of cysteine, hydroxyproline, 
hydroxylysine, and glycine. 
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Pepsin digested Human GBM 
polypeptide 1 00 kDa 
Pepsin digested collagen IV 
polypeptide 100 kOa 
CD~MTSEPGAJV J: 
Amino Acid 
HOP-hydroxyproline J-hexosomines HOL-hydroxylysine 
Figure 20. Indirect Immunofluorescence of Human Renal Cortical 
Tissue with Anti-Collagen IV mAb 
cryostat sectioned human renal cortical tissue was reacted with 10 
ug of anti-collagen IV mAb or MOPC 21. After processing, sections 
were viewed under a fluorescent microscope. In A, reactivity of 
human cortical tissue with anti-collagen IV mAb is shown. Bowman's 
capsule, the GBM and mesangial matrix were reactive with anti-
collagen IV mAb. In B, MOPC 21 did not react with any portion of 
the cortical tissue. Mesangial nuclei were autofluorescent. 
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Reactions of anti-collagen IV mAb and enzyme digested GBMs 
are represented (panel B). Only pepsin and trypsin digested GBMs 
reacted with anti-collagen IV mAb. There was a distinct difference 
in the reactivity of anti-collagen IV mAb with the two trypsin 
digested GBMs shown: at 4 ug/ml anti-collagen IV mAb, trypsin 
digested GBM 4415 N reacted to a significantly lesser extent with 
anti-collagen IV mAb than with GBM 7415 N (p<0.001), but the 
reactivity of GBM 4415 N with anti-collagen IV mAb was significantly 
greater than the reactivity of GBM 4415 N with MOPC 21 (p<0.01). 
Only trypsin and pepsin digested GBMs contained the anti-collagen IV 
mAb epitope. 
The reactivity of anti-collagen IV mAb with collagenase 
digested collagen I or collagen IV and with laminin is represented 
in Panel c. Laminin did not react above background levels of MOPC 
21 reactivity with as much as 20 ug/ml IgGl of anti-collagen IV mAb. 
Collagenase digested collagen I or collagen IV also did not react 
with as much as 20 ug/ml of anti-collagen IV mAb and this very low 
level of reactivity was indistinguishable from reactivity with MOPC 
21 (in both cases, p>0.2). This result is consistent with the data 
presented in Panel B. Pepsin or trypsin digested collagen I or 
collagen IV reacted with anti-collagen IV mAb (Panel D). 
Trypsin or pepsin digested GBM or collagen reacted with anti-
collagen IV mAb to significantly greater degrees than with MOPC 21 
(in all cases and for all IgGl concentrations, p<0.001). 
Collagenase digested GBM or collagen could not react with anti-
collagen IV mAb. These data indicated that the anti-collagen IV mAb 
100 
recognized epitope is destroyed by collagenase treatment and this 
implied that the anti-collagen IV mAb recognized epitope is located 
in the triple helical domain of collagen. 
Fibronectin reacted with anti-collagen IV mAb (panel D). 
This result will be re-evaluated in COMPETITIVE INHIBITION OF ANTI-
COLLAGEN IV mAb REACTIVITY. 
Anti-Collagen 1.Y mAb Reactivity with Trypsin .Q!:. Collagenase Digested 
GBM 
As seen in Figure 21, two collagenase digested GBMs and 
collagenase digested collagen I or IV did not react with anti-
collagen IV mAb. As represented in Figure 22, none of the 
collagenase digested GBMs reacted with anti-collagen IV mAb to any 
significant extent while all trypsin digested GBM could react with 
anti-collagen IV mAb. The collagenase digested GBM most reactive 
was not significantly greater in reactivity with anti-collagen IV 
mAb than any other col lagenase digested GBM (at 5. 0 and 2. 5 ug /ml 
IgGl, p>O.l). 
Competitive Inhibition of Anti-Collagen IV mAb Reactivity 
For a comparison of inhibition of IIF4 reactivity with GBM or 
GBM components, competitive inhibition of anti-collagen IV mAb 
reactivity was performed. Both pepsin digested collagen I and IV 
inhibited anti-collagen IV mAb reactivity to maxima of 88 and 76%, 
respectively at 10,000 ng of collagen I or collagen IV. Neither 
Figure 21. Anti-Collagen IV Reactivity filth Bacterial Membranes, 
Isolated Components of the GBM, and ~ 
Anti-collagen IV mAb reactivity with bacterial cell membranes, 
isolated GBM components, and enzyme digested GBMs was assayed in 
ELISA. Reactivity of anti-collagen IV mAb with trypsin digested SCM 
and §. mutans cell membrane is represented in Panel A. Pepsin or 
trypsin digested collagen I and collagen IV reactions with anti-
collagen IV mAb or MOPC 21 are represented in Panel B. Panel C 
represents anti-collagen IV mAb or MOPC 21 reactivity with laminin 
and collagenase digests of collagen I or IV. Panel D represents 
anti-collagen IV mAb and MOPC 21 reactivity with pepsin or trypsin 
digested collagen IV, pepsin digested collagen I and fibronectin. 
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trypsin digested SCM nor native fibronectin inhibited anti-collagen 
IV mAb reactivity in this assay (Figure 23). The results of these 
assays are summarized in Table 5. 
Summary of Inhibition of Anti-Collagen IV mAb Reactivity 
Neither trypsin digested SCM nor native fibronectin inhibited 
anti-collagen IV mAb reactivity with trypsin digested GBM. Both 
pepsin digested collagen I and collagen IV inhibited anti-collagen 
IV mAb. Approximately twice as much collagen IV as collagen I was 
required to inhibit 40% of anti-collagen IV mAb reactivity. Since 
anti-collagen IV mAb reacted with both types of collagen, this 
result indicated that the anti-collagen IV mAb recognized epitope is 
located in domains shared by collagen IV and collagen I. This is 
the triple helical domain. 
Figure 22. Trypsin Digested GBM and Collagenase Digested GBM Did Not 
React Equally with Anti-Collagen IV mAb 
The reactivity of anti-collagen IV mAb and MOPC 21 with 7 trypsin 
digested GBMs and 12 collagenase digested GBMs is represented. 
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Figure 23. Competitive Inhibition of Anti-Collagen IV mAb Reactivity 
with Collagens I~ IV, Fibronectin, and Trypsin Digested SCM 
Competitive inhibition of anti-collagen IV mAb reactivity was assayed 
as described for IIF4 reactivity in Figure 13 except that 0.5 ug/ml 
anti-collagen IV mAb was used and inhibition of anti-collagen IV mAb 
reactivity was assayed on trypsin digested GBM ELISA plates. Native 
fibronectin, trypsin digested SCM, pepsin digested collagen I and 
pepsin digested collagen IV were used as inhibitors of anti-collagen IV 
mAb reactivity with trypsin digested GBM. A level of 50% inhibition of 
anti-collagen IV mAb reactivity was chosen for comparison of extent of 
anti-collagen IV mAb reactivity and this data is summarized and 
presented in Table 5. 
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TABLE 5. 
SUMMARY OF COMPETITIVE INHIBITION STUDIES 
INHIBITION OF ANTI-COLLAGEN IV mAb REACTIVITY 
Inhibitor 
Trypsin digested SCM 
Human serum fibronectin 
Pepsin digested human 
placenta collagen I 
Pepsin digested human 
placenta collagen IV 
Nanogram amount of inhibitor 
required to achieve 50% 
inhibition of anti-collagen IV 
mAb reactivity 
(at 50 ng of anti-collagen IV mAb) 
NI 
NI 
1000 +/- 240 ng 
2050 +/- 530 ng 
NI-- not inhibitory at 50% inhibition of anti-collagen IV mAb 
reactivity. 
108 
Nanogram inhibitory values were determined from a first order linear 
regression plot of each inhibitor and at 50% inhibition of anti-
collagen IV mAb reactivity. 
DISCUSSION 
The long established clinical association between infection 
with a nephritogenic strain of streptococci and development of 
glomerulonephritis (Futcher, 1940; Stollerman, 1969) has led many 
researchers to speculate upon and examine possible etiologies for 
poststreptococcal glomerulonephritis. One hypothesis is that 
streptococcal component-antibody immune complexes deposit in the GBM 
or complexes form in situ (Friedman et , 1984; Stinson et 
• I 
1983). Another hypothesis this that antigenic relatedness exists 
between the streptococcal cell membrane and a GBM component 
(Markowitz and Lange, 1964; Lange, 1980b; Fitzsimons, Weber, and 
Lange, 1987; Zelman and Lange, 1989). A murine monoclonal antibody 
generated to type 12 SCM was used to investigate the relationship 
between SCM and GBM. 
The first major hypothesis of this thesis is that an anti-SCM 
mAb (IIF4) can react with isolated, human GBM; the second hypothesis 
is that IIF4 will react with the majority of GBMs tested. IIF4 
reacted with isolated, human GBM and IIF4 reacted with all 26 GBMs 
tested. In this study, the IIF4 reactive epitope in GBM was pepsin, 
collagenase, and trypsin insensitive. It was also noted that two 
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groups of GBMs were evident when extent of IIF4 reactivity with the 
panel of GBMs was examined. 
The third hypothesis was that IIF4 would recognize a specific 
component of GBM. This mAb reacted with collagen IV. The fourth 
hypothesis was that IIF4 wou_ld recognize an identifiable location on 
collagen IV. Attempts were made to accomplish this and the data was 
consistent with the IIF4 reactive epitope was in fragments of 
collagen IV which had included part of the triple helical region 
and the NCl globular domain. Comparisons were made between IIF4 and 
a conventional anti-collagen IV mAb; it was seen that these two 
antibodies did not recognize the same epitope; the anti-collagen IV 
mAb recognized epitope was collagenase sensitive. The hypotheses 
addressed in this dissertation were aimed at furthering our 
understanding of the incidence of this epitope in GBM. 
While this evidence does not prove the role of SCM in the 
etiology of poststreptococcal glomerulonephritis, the demonstration 
of the reactivity of an anti-SCM mAb to a GBM antigen does support 
the hypothesis of antigenic relatedness between these two entities. 
These data will be discussed in relation to the two models of 
post streptococcal glomerulonephritis development and the 
significance of reactivity of an anti-SCM mAb with collagen IV. A 
model will be presented for the generation of an anti-SCM mAb 
reactive with GBM and collagen IV and its possible roles in 
poststreptococcal glomerulonephritis. 
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Characterization and Reactivity of the anti-SCM mAb, IIF4 
The first consideration in this study was the partial 
purification, quantitation and characterization of the anti-SCM mAb, 
IIF4. These qualitative and quantitative determinations are the 
basis for the use of IIF4 in all the studies in this dissertation. 
IIF4 was isotyped as IgM (Table l). Murine IgM is known to 
be a characteristically difficult monoclonal antibody with which to 
work. For example, murine IgM is not readily bound to Protein A or 
Protein G (Kronvall, Grey and Williams, 1970; Lindmark, Thoren-
Tolling, and Sjoquist, 1983) which are commonly used to partially 
purify IgG antibody species. In this study, euglobulin prec-
ipitation was found to be an easy, quick and inexpensive means of 
partially purifying murine IgM. Albumin and transferrin are removed 
by euglobulin precipitation from the ascites and primarily IgM and 
IgG3 remain (Garcia-Gonzales et al., 1988). Purity of the 
euglobulin fraction was demonstrated by SDS-PAGE and calculated to 
be 65-85% on average. 
An important consideration in working with murine IgM 
antibodies is that IgM are generally considered to be of low 
affinity. A hallmark of a primary immune reaction is a polyclonal 
IgM response. As the response matures to a secondary reaction, 
dogma states that a relatively few high affinity IgM clones are 
switched to IgG production and expanded while the low affinity 
clones are not expanded. Thus, the isolation of an IgM clone of low 
affinity is potentially high. Affinity data for IIF4 is 
unavailable. However, studies done on naturally occurring IgM 
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producing clones have found these mAbs to be multireactive 
(Rousseau, Mallett, and Smith-Gill, 1989). Naturally occurring IgM 
clones from murine neonates were also found to be multireactive for 
other IgM molecules (Holmberg et al., 1984). In the present study, 
IIF4 and TEPC 183 reactivity with a number of proteins is presented. 
TEPC 183 appears to bind to many proteins to some extent. The TEPC 
183 ligand is not known, but this low level of binding to many 
proteins is probably due to the nature of the IgM molecule. The 
general rule for IgM affinity is low affinity, high valence number 
and high affinity, low valence number. It has been noted in some 
IgM molecules that approximately half the binding sites are 
relatively higher affinity than the other binding sites; the authors 
did not ascribe this to different combining sites in one molecule, 
but the effect of conformation of the decavalent IgM molecule 
(Pascual and Clem, 1988). Lower affinity sites could lead to 
increased nonspecific binding of the IgM antibody. However, TEPC 
183 is used here as an isotyped match to control for any nonspecific 
binding of murine IgM which may be expected in these types of 
experiments. Statistical data is given to indicate when the IIF4 or 
TEPC 183 reactivity with a protein is significantly different. 
IIF4 reactivity was characterized with its autologous 
antigen, SCM, and another streptococcal cell membrane from ~. 
mutans. The use of the cell membrane from §. mutans was appropriate 
for the comparison with SCM since §. mutans cell membrane has been 
cited as having an immunological relationship with heart muscle (Van 
De Rijn, Bleiweis, and Zabriskie, 1976; Hughes et al., 1980) and 
113 
kidney tissue (Albini et al., 1985). Human anti-heart sera was 
capable of binding polypeptides from ~. mutans cell membrane 
(Ayakawa et al., 1985). Disrupted ~- mutans has been used in the 
generation of sera and the sera was capable of binding to human GBM 
and heart muscle and this reactivity could be absorbed by the cell 
membrane (Nisengard, Stinson, and Pelonero, 1983). ~- mutans has 
also been implicated in the generation of glomerulonephritis. 
Disrupted streptococci injected into rabbits resulted in 
poststreptococcal-like kidney pathology and deposition of ~· mutans 
antigens in the GBM (Albini et al., 1985). Thus, evidence does exist 
that ~. mutans, possibly the cell membrane, and heart and kidney 
tissue share a common antigen. 
IIF4 was found to react significantly with SCM and not with 
.§.. mutans cell membrane (Figure 1). Furthermore, TEPC 183, was 
found to react significantly less with SCM than IIF4 did with SCM. 
Competitive inhibition of IIF4 reactivity to SCM was tested with SCM 
and .§.. mutans cell membranes as inhibitors (Figure 2). SCM did 
inhibit IIF4 reactivity with SCM while .§.. mutans cell membrane was 
unable to inhibit IIF4 reactivity to any extent distinguishable from 
background. These two sets of data confirmed that the IIF4 reactive 
epitope resides in its homologous antigen, SCM, and not in another 
streptococcal cell membrane from .§.. mutans. 
Characterization of GBMs and IIF4 Reactivity with ~ 
The first major hypothesis of this thesis was that IIF4, an 
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anti-SCM mAB, reacts with GBM. In indirect immunofluorescence, IIF4 
was found to bind to renal cortical GBM, mesangial matrix and 
tubular basement membrane {Figure 3A). The green 
immunofluorescence due to IIF4 that stained the GBM, mesangial matr-
ix, and tubular basement membrane was of a spotty or hazy, granular 
nature. Others have reported a granular type pattern seen in human 
kidneys using a monoclonal antibody generated to cultured glomerular 
cells {Nakamura, 1986). Antibodies derived from patients with acute 
poststreptococcal glomerulonephritis stained glomeruli from these 
patients in a granular pattern (Yoshizawa al., 1973). The 
localization of fluorescence in the renal cortical tissue is 
consistent with the IIF4 recognized epitope as a component of the 
GBM, tubular basement membrane, and in association with the 
mesangial cells. 
Autofluorescent (yellow-orange) mesangial nuclei were found 
in all renal tissues examined regardless of antibody type used in 
the experiment. The autofluorescence is helpful in recognizing 
anatomical structures; for example, the unique cellular array of the 
glomeruli or tubules is readily evident. This condition may be due 
to the variable time interval between demise, autopsy and freezing 
of the kidney tissue. Autodegradation is commonly known to occur 
and the variable intensity of nuclear autofluorescence may be due to 
breakdown and exposure of nuclear compounds in the tissues. 
As a comparison, anti-collagen IV mAb was used to stain human 
kidneys; a linear pattern was seen. Other anti-GBM sera have 
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stained GBM in linear patterns. Acid eluates from kidney biopsies 
of patients with Goodpasture's syndrome yielded antibodies reactive 
with GBM in a linear fashion (Lerner, Glasscock, and Dixon, 1967). 
Monoclonal antibodies developed to collagenase solubilized GBM also 
produced linear patterns along the GBM (Pusey et al., 1987). When a 
heterologous rabbit anti-human GBM anti-serum was generated, it 
stained human kidney tissue in a linear pattern with intense 
staining of the inner endothelial zone and outer epithelial zone 
with mesangial matrix involvement (Fish et ., 1983). Antibodies 
from a patient with anti-GBM nephritis, as well as an anti-NCl sera, 
produced a linear staining pattern on normal human kidney sections 
(Thorner et al., 1989). Antiserum to components of the GBM such as 
heparan sulfate proteoglycan produced intense linear patterns along 
the GBM (Van Den Heuvel al., 1989). Clinically, the type of 
fluorescence seen is used as a diagnostic sign and are classed as 
starry sky (fine granular deposits of IgG/IgM and C3), mesangial (C3 
deposits), or garland (IgG and C3 deposits) (Sorger et al., 1983; 
Rodriguez-Iturbe, 1984). The ultrastructural significance of any 
type of staining is unknown, but each type may reflect a distinct 
antibody reactivity localization with a component or components of 
the GBM. 
In order to characterize the indicated IIF4 reactivity in the 
GBM, GBM was isolated from 26 human kidneys (Greenspan and Krakawer, 
1950; Carlson et al., 1978). A conunon method of GBM characterization 
is amino acid analysis (Wieslander, 1983; Spiro, 1967; Kefalides, 
1972; Lange, 1969). While this method cannot determine the identity 
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of proteins comprising the GBM, this method can demonstrate 
characteristic amino acids of known proteins. The 25 GBMs assayed 
for amino acid composition revealed the presence of hydroxyproline 
and hydroxylysine (Table 2); these amino acids are found only in 
collagenous proteins. The amino acid composition analysis of the 25 
GBMs is consistent with previously reported GBM analyses in that 
hydroxyproline, hydroxylysine and a high glycine level (greater than 
or equal to 10%) are present (Wieslander, 1983; Westberg and 
Michael, 1970) . 
The panel of GBMs was further characterized by reactivity 
with IIF4. All 26 individual GBM preparations reacted with IIF4. 
These data indicate that all GBMs (in this study) contain the IIF4 
recognized epitope. This study was differentiated from other studies 
of antibody reacting with GBM by using a panel of 26 human GBMs and 
examined anti-SCM mAb reactivity to each GBM. Previously, studies 
have been conducted with human GBM using a pool of several GBMs 
(Westberg and Michael, 1970; Wieslander, 1983; Lange, 1980b; 
Markowitz and Lange, 1964). The reactivity of anti-SCM sera with 
individual GBMs was also studied (Blue and Lange, 1976; Lange, 1969; 
Lange, 1980a). These studies indicated that an anti-SCM sera could 
react with glomeruli in tissue sections, but since sera were used, 
the shared epitope concept could not be invoked. This study was 
also unique in that the panel of human GBMs was screened for 
reactivity with an anti-SCM mAb. Other studies have looked at the 
reactivity of GBM components with a patient's serum; this is 
especially true for reactivity of Goodpasture's patients serum 
117 
reacting with the NCl domain of collagen IV which was derived from a 
pool of human GBM tissue (Pusey et al., 1987; Weber, Meyer zum 
Buschenfelde and K hler, 1988; Fish et 1984). Extensive 
studies have characterized Goodpasture's patient serum reacting 
specifically with monomers .of 26 kDa and dimers of 52 kDa derived 
from the NCl domain of collagen IV. This antigen is the best 
characterized glomerular polypeptide involved in autoreactivity. 
Other studies have characterized the GBM with monoclonal an-
tibodies reactive with protein components of the GBM such as laminin 
(Kefalides et al., 1986) and heparan sulfate proteoglycan (Van Den 
Heuvel et al., 1989; Edge and Spiro, 1987). These studies have 
sought to define the structure and the role of the individual 
components in a basement membrane complex. In distinction, studies 
with anti-SCM mAb seek to characterize the reactivity of such 
antibodies with human GBMs and focus on the presence of the IIF4 
reactive epitope in that GBM component. 
Relatively high and low IIF4-reactive groups of GBMs could be 
seen. There are several possible explanations for this variability 
seen in extent of IIF4 reactivity (Figures 7, B, and 9). The GBMs 
used in this study were each isolated from human kidneys. Each 
kidney was collected and frozen upon autopsy at variable times after 
death. This is an uncontrolled factor in these experiments; it is 
well known that autolysis will take place in tissue after demise and 
evidence of autodegradation was seen in the autofluorescence of 
mesangial nuclei in all tissues examined. However, each GBM was 
isolated and enzyme digested under equivalent conditions. Variable 
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amounts of autolysis had most likely taken place in each kidney 
prior to GBM isolation and enzyme digestion. The IIF4 reactive 
epitope may be more readily available for binding in some GBM 
preparations than in others. This may be due to the complex 
structure of the components of GBM when the GBM is enzyme 
solubilized. The IIF4 reactive epitope may occur in varying 
densities in each GBM. These experiments can not distinguish among 
these possibilities of the variation seen of IIF4 reactivity with 
the GBMs. 
IIF4 also reacted equivalently with pepsin, collagenase or 
trypsin digested GBM (Figure 7, panel B); thus, the IIF4 reactive 
epitope was trypsin, collagenase, and pepsin insensitive. Bacterial 
collagenase specifically cleaves the peptide bond in collagen 
molecules between the .. Y .. and the glycine residues in the "Gly-X-Y-
Gly-X-Y" repeating triplet of the triple helical of the collagen 
molecule (Harper, 1980). Trypsin is highly specific for positively 
charged side chains with arginine and lysine (Brown and Wold, 1973). 
Pepsin cleaves proteins at aromatic amino acids (Ryle, 1970). The 
data generated here indicated that the IIF4 reactive epitope was not 
part of the triple helical region of collagen, did not have an 
arginine/lysine within or near the epitope, and did not contain 
aromatic amino acids. 
Characterization of IIF4 Reactivity with Components of GBM 
The next goal of this dissertation was to identify the IIF4 
reactive GBM component. This was accomplished by examining major 
components of the GBM for IIF4 reactivity. 
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IIF4 reacted to an 
equivalent extent with collagenase digested collagen IV and collagen 
I, with trypsin digested collagen I, and with pepsin digested 
collagen I and collagen IV (Figure 7). This data clearly targets 
the IIF4 reactive protein as collagen. In order to confirm IIF4 
reactivity, another method was employed. 
IIF4 reactivity with enzyme digested GBMs, enzyme digested 
collagen I and collagen IV, and other major components of GBM was 
evaluated by competitive inhibition. Trypsin, collagenase or pepsin 
digested GBM all inhibited IIF4 reactivity significantly. Twice the 
amount of collagenase or pepsin digested GBM was required to achieve 
the same extent of inhibition as trypsin digested GBM. Possible 
explanations of this result are that more IIF4 reactive epitopes 
exist in the trypsin digested GBM or trypsin digestion best opens up 
the quaternary structure of the GBM to reveal IIF4 reactive 
epitopes. In any case, all enzyme digests of GBM significantly (at 
least 40%) inhibited IIF4 reactivity with SCM. 
Low molecular weight, trypsin digestion derived, murine GBM 
polypeptides were found to competitively inhibit anti-SCM mAb 
reactivity with SCM peptides (Zelman and Lange, 1989). It was seen 
that 20 pM of a 5 kDa GBM peptide completely inhibited the 
reactivity of 12.5 pM of anti-SCM mAb. The interpretation of these 
and other data was that the 5 kDa fragment contained two epitopes 
available for anti-SCM mAb binding. These studies also stressed the 
importance of the size of the epitope containing fragment. As the 
epitope containing fragment increased in size, the more eteric 
hindrance of binding by the paratope became important. 
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In the 
present study, the native size of the pepsin or collagen digested 
collagen IV polypeptide bound to IIF4 is unknown, but if the 
polypeptides are assumed to be an average of 200 kDa, 5. 8 pM of 
pepsin digested collagen IV. were required to inhibit (at 40%) 1 pM 
of IIF4. Likewise, 20 pM of collagenase digested collagen IV were 
required to inhibit (at 40%) 1 pM of IIF4. The polypeptides from 
the pepsin digests are probably large, since extensive reduction is 
required to produce smaller (-100 kDa) pepsin fragments (Glanville 
et al., 1985). Interference of paratope binding due to steric 
hindrance of large c-200 kDa) polypeptides may explain the large 
amount of antigen needed to inhibit antibody activity. These 
results confirmed that IIF4 exhibited specific binding to human GBM 
and to a collagen molecule. 
Other major components of the GBM were used as competitors of 
IIF4 reactivity with SCM. Neither human serum fibronectin, bovine 
kidney heparan sulfate proteoglycan nor murine sarcoma derived 
laminin could inhibit IIF4 reactivity with SCM to any extent 
distinguishable from no inhibition of IIF4 reactivity. Fibronectin 
was used in these studies since fibronectin can be associated with 
collagen IV, although not a native part of GBM (Mauger et al., 1987; 
Hahn et al., 1980). These results demonstrated that these major 
components of the GBM did not contain the IIF4 reactive epitope. 
IIF4 had reactivity with collagenase, trypsin, or pepsin 
digested collagen I (Figure 7) which is not a reported constituent 
of GBM (Timpl, 1989). Pepsin digested collagen I was unable to 
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competitively inhibit IIF4 reactivity (Figure 8). Solution based 
competitive inhibition is a common method used to confirm antibody 
reactivity (Zelman and Lange, 1989; Dale and Beachey, 1985; 
Cunningham et al., 1989; Kraus et al., 1989). solid phase assays 
are considered more sensitive for high affinity antibodies while 
fluid phase assays, such as a Farr assay, are considered more 
sensitive for lower affinity antibodies (Kennel, 1982; Nimmo et al., 
1984; Butler et al., 1978; Peterman, Voss and Butler, 1985). In 
these assays, a fluid phase assay, competitive inhibition, may be 
more reliable for determination of murine IgM reactivity. Epitopes 
shared by collagen types have been easily detectable by ELISA and 
Western blot. In a study of familial nephritis, IgA patient serum 
reacted with the triple helical domain of collagens I, II, and IV, 
indicating that antibodies directed to this moderately conserved 
domain will have a wide span of reactivity with types of collagen 
(Cederholm et al., 1986). Thus, based on the isotype used and the 
reported sensitivity of these assays when using IgM, it seems 
unlikely that collagen I is a IIF4 target antigen. 
IIF4 reactivity with SCM was significantly inhibited by 
enzyme digests of collagen IV. Collagenase digested GBM or collagen 
IV inhibited IIF4 reactivity with SCM to approximately the same 
extent. This may be due to the fact that GBM and isolated collagen 
IV are somewhat resistant to collagenase digestion (Cederholm et 
al., 1986; Risteli et al., 1980; Siebold et al., 1987). The 
products of collagenase digestion of collagen IV are large ( -100 
kDa) polypeptide chains which are highly associated with one 
another. 
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Possibly, collagenase digestion of GBM or collagen IV 
reveals a limited number of IIF4 reactive epitopea even though 
collagen IV was purified away from other placental basement membrane 
constituents. 
Three times the amount of pepsin digested GBM as pepsin 
digested collagen IV was needed to inhibit IIF4 reactivity to the 
same extent. Pepsin digests of isolated collagen IV are commonly 
used to study collagen IV polypeptides (Glanville et al., 1985; Qian 
and Glanville, 1984; Glanville, Rauter, and Fietzek, 1979) and it is 
known that pepsin digestion of collagen IV produces large (-95 kDa) 
polypeptide chains (Qian and Glanville, 1984; Glanville et al., 
1985). This data suggested an approximate 3 fold increase or 
enrichment of available IIF4 reactive epitopes in isolated, pepsin 
digested collagen IV as compared to pepsin digested GBM. Pepsin 
digested collagen IV inhibited IIF4 reactivity with SCM the greatest 
extent among all enzyme digests of GBM and collagen IV assayed. 
Trypsin digested SCM and pepsin digested collagen IV were able to 
inhibit IIF4 reactivity to pepsin digested collagen IV (Figure 9). 
Pepsin digested collagen IV could achieve 40% inhibition of IIF4 
reactivity with amounts of pepsin digested collagen IV comparable to 
those needed to inhibit IIF4 reactivity with SCM (Table 3). 
However, twice as much SCM was required to inhibit IIF4 reactivity 
with pepsin digested collagen IV as with SCM. This may be due to 
better availability of the IIF4 reactive epitope in the complex of 
pepsin digested collagen IV polypeptides as compared to the complex 
of trypsin digested SCM polypeptides. This trend was also apparent 
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in the collagen IV inhibition of IIF4 reactivity with SCM (Table 3). 
These experiments demonstrated that collagen IV contained the IIF4 
reactive epitope and these results indicated that the binding 
availability or incidence of available epitopes was greater in 
pepsin digested collagen IV polypeptides than in trypsin digested 
SCM polypeptides. 
Characterization of IIF4 Reactive Polypeptides in GBM and Collagen 
The next purpose of this dissertation was to identify the 
portion or domain of collagen IV reactive with IIF4. The method 
chosen to answer this question was immunoprecipitation of enzyme 
digested GBM, collagen IV, and other GBM components by IIF4 and 
goat-anti-mouse IgM coupled agarose and separation on SDS-PAGE. 
This was the most economical, technically simple and widely accepted 
method available for demonstrating reactions of an antibody with 
specific proteins, polypeptides, or peptides (Weir, 1986; Chen et 
al. , 1986). In this type of experiment, the eluted, 
immunoprecipitated material contains IgM, IgG derived from the goat 
anti-mouse agarose beads, and proteins bound to IgM, if any. Thus, 
the eluted material contains mu chain (65 kDa), gamma chain (51 
kDa), light chains (30 kDa), J chain from IgM ( 16 kDa), and any 
immunoprecipitated proteins. Results presented contain a 
representation of material eluted from the goat anti-mouse IgM 
agarose beads/antibody complex as well as the beads alone and 
demonstrated on silver stained SOS-PAGE. Material eluted from the 
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goat anti-mouse IgM agarose beads contains polypeptides other than 
only garmna and light chain; polypeptides of 37, 40, 44, 55, and 66 
kDa have been detected (Figures 10, 118, 12, and 14). These 
polypeptides are of unknown origin, but are derived from the beads 
or antibodies themselves. Polypeptides of these molecular weights 
are not considered immunoprecipitated when they are present in the 
representation of a IIF4 or TEPC 183 immunoprecipitated sample. 
Polypeptides which appear in IIF4 immunoprecipitated sample as well 
as in the TEPC 183 irnmunoprecipitated control are considered 
nonspecific. Immunoprecipitated proteins of molecular weight equal 
or similar to any of the antibody chains may be undetected. This 
method can, however, detect immunoprecipitated polypeptides that are 
reproducibly present and of a molecular weight distinct from the 
antibody chains. 
As summarized in Table 4, the IIF4 irnmunoprecipitation of 
polypeptides from collagenase or pepsin digested GBM, collagen I, 
collagen IV and laminin indicated that IIF4 generally reacted with 
GBM and collagen IV polypeptides of 100-200 kDa. In four GBM 
samples, other IIF4 reactive polypeptides from collagenase digested 
GBM of lower molecular weight were seen (Figure 10, 11 B, and 14). 
IIF4 reacted with -200, 140, 100, and 60 kDa polypeptides from 
pepsin digested GBM (Figure 15). It was also suggested that IIF4 
was reactive with polypeptides of -200, 140, and 90 kDa from pepsin 
digested collagen IV (Figure 17A); in this experiment, TEPC 183 was 
seen to have some reactivity with these collagen IV polypeptides. 
IIF4 did not react with polypeptides from pepsin digested collagen I 
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or native laminin (Figure 17B). With the exception of pepsin 
digested collagen IV polypeptides, these results strongly supported 
and were in agreement with data that demonstrated the IIF4 reactive 
GBM component was collagen IV. 
Although these experiments indicated IIF4 reactive 
polypeptides of similar or equivalent molecular weight from digests 
of collagen IV or GBM, these experiments did not identify the domain 
of collagen IV reactive with IIF4. Collagenase digests of GBM and 
of collagen IV contain polypeptides of 54 and 26 kDa that are 
reactive with anti-Goodpasture's antibody (Pusey et al., 1987; Weber 
et al., 1987). An antigen reactive to Goodpasture antibody has been 
identified as residing in a 26 kDa monomer of the NCl globular 
domain of collagen IV (Pusey al., 1987; Butkowski et al., 1985; 
Wieslander, Kataja, and Hudson, 1987). IIF4 reacted in only one 
case with a 27 kDa polypeptide from collagenase digested GBM (Figure 
14), but this was not seen in IIF4 reactivity with collagenase 
digested collagen IV. A 45 kDa polypeptide from collagenase 
digested collagen IV was IIF4 reactive, but this molecular weight 
has not been reported for the dimer form of the Goodpasture' s 
antigen (Pusey et al., 1987). This indicates that the IIF4 reactive 
epitope is probably not the Goodpasture' s antigen; however, this 
does not rule not other possible epitopes in the NCl globular domain 
of collagen IV as IIF4 reactive. 
Interstitial collagen I and basement membrane collagen IV 
differ in tissue distribution (Kuhn, 1987), but share sequence 
similarity in their triple helical regions. This large domain in 
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both types of collagen is predominantly "Gly-X-Y" repeating triplets 
in three chains that are wound around each other. There is a small 
amount of dissimilarity amongst the triple helical domains of 
collagen I and collagen IV. The most striking difference between 
the two collagen types is that collagen I has no globular domains at 
its amino and carboxyl termini. IIF4 was not reactive with collagen 
I in competitive inhibition with IIF4 or immunoprecipitation with 
IIF4. This suggested that IIF4 was reactive with a globular domain 
in collagen IV. The 7S and NCl globular domains are the largest 
globular domains in collagen IV and are structurally prominent 
(Yurchenco, 1990; Yurchenco et al., 1986; Yurchenco and Furthmayr, 
1984). Human collagen IV alpha l(IV) chain does contain 21 
globular-like interruptions of its triple helical domain that are 8 
amino acid residues or larger; the human alpha 2(IV) chain has 23 
similar globular interruptions of its triple helix. 
is unique to collagen IV (Brazel et al., 1988). 
This property 
These globular 
domains are possible candidates for the location of IIF4 reactivity 
as suggested by these studies. 
IIF4 reactive polypeptides from pepsin digested GBM were 100 
and 85 kDa. Pepsin digestion and reduction of collagen IV yields 
polypeptides of 140 (alpha 1 chain), 120 (alpha 2), 100 (alpha 1), 
75 (alpha 2), 50, and 25 kDa (Qian and Glanville, 1984; Brazel et 
al., 1988; Glanville and Rauter, 1981). These polypeptides from 
pepsin digested collagen IV have been identified as entire or a 
slightly truncated versions of the two types of alpha chains 
commonly found in collagen IV (Qian and Glanville, 1984; Glanville 
et al., 1985) • 
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The 100 kDa polypeptide from pepsin digestion of 
collagen IV has been sequenced (Qian and Glanville, 1984). Although 
there has been much confusion in the literature, it has been 
determined that these polypeptides originate in the NCl globular 
domain (Glanville, 1987). IIF4 was not shown to specifically 
irnrnunoprecipitate polypeptides of these molecular weights from 
pepsin digested collagen IV; TEPC 183 had some reactivity with these 
polypeptides (Figure 17A). However, the determination of collagen 
IV as the GBM protein reactive with IIF4 and the demonstration of 
pepsin digested GBM polypeptides of 100 and 85 kDa as IIF4 reactive 
targeted similar collagen IV polypeptides as containing the IIF4 
reactive epitope. 
In studies using an mAb to type IV collagen, reduced 
polypeptides from a crude pepsin digestion of collagen IV were found 
to be 180, 140, 120, 90, 40, and 15 kDa with a nonreduced size of 
260 kDa (Kina et al., 1988). This mAb did not react with collagen I, 
collagen v, collagen III, collagenase digested collagen IV, 
fibronectin or laminin. It did react with denatured collagen IV 
indicating that the epitope was not part of the triple helical 
conformation or conformation defined. Amino acid analysis of the 
native pepsin digested collagen IV polypeptide reactive with this 
mAb indicated 15 cysteine residues in this polypeptide. The authors 
speculated that these pepsin digest fragments originated in the NCl 
domain. 
In another study, a mAb generated to collagen IV was found 
to react with a high molecular weight (250 kDa) polypeptide that 
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could be localized to placenta, bovine lens capsule, and GBM. This 
polypeptide was pepsin and collagenase resistant and distinct from 
alpha 1 (IV) and alpha 2 (IV). Anti-serum to this polypeptides 
stained the GBM in a linear pattern with mesangial involvement. The 
authors postulated that this may be a new alpha chain or possibly 
the alpha 4(IV) (Scheinman and Tsai, 1984). Both of these studies 
indicate that collagen IV is a highly complex molecule with many 
potential sites that are capable of eliciting antibody generation. 
Sequencing of the IIF4 reactive polypeptides to identify the 
IIF4 epitope was impractical. The polypeptides were too large for 
sequencing and too large to allow for the identification of the IIF4 
reactive epitope. However, in order to support the hypothesis that 
the IIF4 reactive polypeptides originated in the NCl domain, the 
IIF4 reactive polypeptides were isolated and subjected to amino acid 
analysis. The IIF4 reactive polypeptides from collagenase digested 
GBM or collagen IV (120 and 100 kDa) were similar in the content of 
some amino acids. Of particular note is the cysteine residue 
content. In a 120 or 100 kDa polypeptide, a 2-4% cysteine reside 
content corresponds to approximately 13-32 cysteine residues. 
Similarly, the IIF4 reactive polypeptide from pepsin digested GBM 
and the equivalently sized polypeptide from pepsin digested collagen 
IV had high cysteine content (30 residues). High cysteine content 
was previously noted in peptide mapped GBM fragments (Lange, 1969). 
This data is consistent with the IIF4 reactive polypeptides in GBM, 
and potentially in collagen IV, as consisting of part of the triple 
helical and NCl domains. 
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Reactivity of Anti-Collagen IV mAb with GBM 
Having shown that IIF4 was reactive with collagen IV, it was 
prudent to compare its reactivity to that of an anti-collagen IV mAb 
and examine differences and similarities in their reactivity with 
GBM and GBM components. Significantly, anti-collagen IV mAb reacted 
with GBM differently than did IIF4 in indirect immunofluorescence. 
A linear pattern of antibody binding along the GBM was seen with 
anti-collagen IV mAb while IIF4 stained the GBM in a granular 
pattern. Additionally, other whole anti-GBM anti-sera are known to 
stain GBM in a linear pattern (Thorner et al., 1989; Fish et al., 
1984) . These data suggest that the IIF4 recognized epitope in GBM 
was different than the epitope recognized by anti-collagen IV mAb. 
Anti-collagen IV mAb did not react with trypsin digested SCM, 
~· mutans cell membrane, laminin or fibronectin; this was the 
expected result. Anti-collagen IV mAb did react with isolated, 
trypsin or pepsin digested GBM or collagen IV, but not with 
collagenase digested GBM or collagen IV. These results indicate 
that the anti-collagen IV mAb recognized epitope was collagenase 
sensitive. The IIF4 recognized epitope, however, was not 
collagenase sensitive. Collagenase digestion of collagen IV and GBM 
is known to be incomplete (Risteli et al., 1980). Possibly the 
anti-collagen IV mAb reactive epitope is part of the interwinding 
superstructure of the three alpha chains of collagen IV at exposed 
sites and can be cleaved by collagenase treatment. Again, these 
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data suggested that the IIF4 reactive epitope was not part of the 
Gly-X-Y repeating unit. 
Anti-collagen IV mAb also reacted with pepsin digested 
collagen I. At 50% inhibition of anti-collagen IV mAb reactivity, 
twice the amount of collagen IV was required to inhibit the mAb as 
was required of collagen I. This may be due to the availability of 
the epitope in these two collagens. 
These data, along with the inability of anti-collagen IV mAb 
to react with collagenase digested GBM or collagen IV indicated that 
the anti-collagen IV mAb epitope was located on the triple helical 
region of collagen molecules. In contrast, it was suggested that 
IIF4 reactivity could not be inhibited by collagen I, but did react 
with collagenase digested GBM or collagen IV. These two mAbs 
clearly recognized different epitopes in the same collagen molecule. 
Significance of IIF4 Reactivity with Collagen IV 
The reactivity of IIF4 with collagen IV is significant in two 
areas; molecular mimicry and development of glomerulonephritis. 
l· Significance of anti-SCM mAb reactivity with collagen IV in 
molecular mimicry. 
The concept of molecular mimicry is based on the antigenic 
relatedness of two distinctly different antigens. Many autoimmune 
diseases have been implicated as having a basis in molecular 
mimicry. The classic example of this is of ankylosing spondylitis 
(AS). The development of arthritis in AS has been linked to 
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infection with Salmonella, Shigella, Yersinia, and especially with 
Klebsiella pneumoniae. The HLA 827 molecule and the ~. pneumoniae 
nitrogenase were reported to share an epitope (Schwimmbeck, Yu and 
Oldstone, 1987); this shared epitope would explain the high 
incidence of AS patients who are HLA 827+. Other bacterial proteins 
have been implicated in sharing epitopes with mammalian tissue and 
correlated with incidence of autoimmune disease. Evidence supports 
a shared epitope between streptococcal M proteins and cardiac myosin 
(Krisher and Cunningham, 1985; Dale and 8eachey, 1985) and this 
relationship has been implicated in the development of rheumatic 
fever. Hepatitis 8 virus polymerase and the encephalitogenic site 
of myelin basic protein are believed to share an epitope and be 
involved in the etiology of experimental allergic encephalomyelitis 
(EAE) (Fujinami and Oldstone, 1985). Ankylosing spondylitis, 
rheumatic fever, and EAE are all be thought to be caused by foreign 
antigens which share epitopes with host tissue; infection with these 
agents may induce an autoimmune response. This study indicated that 
anti-SCM mAb, IIF4, reacted with collagen IV; this adds more 
evidence for the existence of molecular mimicry which could 
theoretically lead to an autoimmune response. 
i. Development of poststreptococcal glomerulonephritis, CPSGN) 
One theory of the etiology of PSGN is that immune complexes 
are formed in the circulation or in situ at the G8M with 
streptococcal antigens (Cameron, 1982; Rodriguez-Iturbe, 1984; 
Friedman et al., 1984). In this model, circulating streptococcal 
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antigens bind with IgG or IgM and are deposited in the kidney. 
Complement is activated; vasoactive peptides are released and 
mediate vascular permeability, chemotaxis and activation of 
neutrophils. Neutrophils enter the tissue and attempt to phagocytize 
the immune complexes. If phagocytosis is not accomplished due to 
size, location or tightness of binding of the immune complex to the 
GBM, the neutrophil releases its lysosomal enzymes and GBM damage 
results (Williams, 1987). 
renal function failure. 
This leads to loss of GBM integrity and 
The data presented here does not support or refute the immune 
complex model for development of post streptococcal 
glomerulonephritis, however, it does support a second model. In 
the second model, antibodies evoked by streptococcal antigens are 
directed to a common epitope located in the GBM (Lange, 1980a; 
Markowitz and Lange, 1964). A monoclonal antibody, IIF4, generated 
to type 12 SCM was shown to react with collagen IV. IIF4 reactivity 
with collagen IV alone does not prove, but ·indicates that SCM and 
GBM share an epitope. Formal proof of a shared epitope requires the 
isolation of and sequencing of small, IIF4 reactive peptides from 
GBM and SCM, but attempts to date have been unsuccessful (Zelman and 
Lange, 1989). 
Collagen IV is found in all basement membranes: skin, 
placenta, kidney, gut, lung, cornea and blood vessels (Glanville, 
1987). Thus, the reactivity of anti-SCM mAb with collagen IV has 
implications beyond that of reactivity with 9lomerular components 
alone; other basement membranes may be targets for anti-SCM 
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antibodies present after streptococcal infection or autoantibodies. 
It is possible that a IIF4-like antibody could bind to the epitope 
in collagen IV in another basement membrane. Upon basement membrane 
damage, an immune complex of IIF4-like antibody and collagen IV 
fragment could be carried to and lodged in the GBM. This is another 
mechanism by which GBM may be damaged by a IIF4-like antibody, but 
this model, in an immune complex with a self antigen. 
In this study, IIF4 reacted with all the panel of isolated 
GBM from normal kidney tissue. Presumably, not all 26 tissue 
sources were infected with type 12 streptococci at the time of 
demise; no overt kidney pathology was noted. It is possible that 
the epitope recognized is present in all GBMs. This study indicated 
100% incidence of the epitope in the GBMs tested. A precedent for 
the widespread occurrence of an basement membrane autoantigen is the 
Goodpasture antigen. It too appears ubiquitously in basement 
membrane containing tissues and is present in bovine basement 
membranes (Hudson et al., 1989). The Goodpasture antigen appears to 
be required for renal integrity and function; a strain of Samoyed 
dogs who have been shown to lack the Goodpasture antigen frequently 
present with renal failure and complete loss of integrity of the GBM 
(Thorner et al., 1988). There is no strong indication from this 
present study that the IIF4 reactive collagen IV epitope is or is 
not the Goodpasture antigen. However, injection of a related anti-
SCM mAb or intraperitoneal injection of the antibody-producing 
hybridoma cells into uninfected mice caused lung and kidney 
pathology highly similar to that found in patients with Goodpasture 
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syndrome (Fitzsimons and Lange, 1991). This may indicate that the 
IIF4 reactive epitope is related to the Goodpasture antigen and this 
awaits further study. 
These data support the model of a common epitope between SCM 
and the GBM component, collagen IV, and the autoimmune component of 
poststreptococcal glomerulonephritis. 
Model for development of poststreptococcal glomerulonephritis: GBM 
damage caused !2Y antibodies reactive with ,a common epitope in SCM 
and GBM 
Host protection from infection with a nephritogenic strain of 
streptococci involves bacterial elimination by opsonization. Host 
failure to produce opsonizing antibodies or subsequent release of 
streptococcal components after phagocytic bacterial destruction 
would allow the host to produce antibodies against streptococcal 
cell membrane antigens. These antibodies may arise from newly 
stimulated pre-existing autoreactive clones or they may arise de 
This model predicts that IIF4 reactive epitope need not be 
sequestered, as is the belief with the Goodpasture antigen, since a 
foreign antigen evokes the antibodies. This may imply that a form 
of control over the development of autoreactive antibodies to the 
IIF4 reactive epitope is operating (such as suppression of 
autoreactive clones). GBM damage, loss of integrity and renal 
failure would follow the same course as described for the immune 
complex model. However, the anti-SCM antibodies are specific for an 
self antigen and thus are autoantibodies. Anti-SCM antibodies may 
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bind directly to collagen IV in the GBM or collagen IV in other 
basement membranes in the body and may lodge in the GBM as an immune 
complex with a fragment of collagen IV as an autoantigen. Anti-
collagen IV reagents are directed to the majority of the GBM in 
immunofluorescence. IIF4, however, bound to GBM in a granular and 
less contiguous pattern. This may indicate potential initiation 
sites of GBM damage if autoantibodies are evoked. The GBM is 
exposed to the vascular flow by the fenestration of the endothelia; 
it is not privileged and is available for binding autoantibodies. 
Collagen IV comprises the majority of the GBM and it is an integral 
part of the structure and function of the GBM. Damage to the GBM 
and subsequent loss of renal function is a serious, possible 
consequence of host response to an epitope shared by SCM and GBM. 
SUMMARY 
The etiology of poststreptococcal glomerulonephritis is 
unknown, but development of glomerulonephritis after infection with 
a nephritogenic strain of streptococci has long been clinically 
correlated. The major purpose of this thesis was to investigate the 
antigenic relatedness between group A type 12 SCM and human GBM. 
Anti-type 12 SCM mAb, IIF4, was specifically reactive with 
its autologous antigen, SCM, and not cell membrane from ~· mutans. 
SCM was hypothesized to contain an epitope also expressed in GBM. 
This hypothesis was substantiated by experiments demonstrating IIF4 
reactivity with GBM, mesangial matrix and tubular basement membrane 
in human renal cortical tissue in indirect irnmunofluorescence. IIF4 
reacted with all individuals in a panel of 26 isolated, enzyme 
digested human GBMs to a significantly greater extent than an 
isotype matched control did with all GBMs. IIF4 reacted to an 
equivalent extent with trypsin, collagenase or pepsin digested GBMs 
indicating that the IIF4 recognized epitope is insensitive to these 
enzymes. Two populations of IIF4 highly and moderately reactive 
GBMs were noted. 
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IIF4 was hypothesized to react with a component of GBM. 
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IIF4 
was established to react with collagen IV, a major component of GBM, 
and not with laminin, fibronectin, heparan sulfate proteoglycan, or 
a related collagen, collagen I. This data also suggested that the 
IIF4 recognized epitope may reside in a globular portion of collagen 
IV. An attempt was made to isolate the IIF4 reactive component of 
collagen IV and of GBM. Size and amino acid content, especially 
cysteine content, of pepsin digested fragments of GBM were 
consistent with the polypeptides consisting of a portion of the 
triple helical domain and of the NCl domain of collagen IV. 
IIF4 reactivity and anti-collagen IV mAb reactivity with 
isolated GBMs and collagen IV was compared. The anti-collagen IV 
mAb recognized epitope in GBM, collagen IV, and collagen I was 
collagenase sensitive; this suggested that the anti-collagen IV mAb 
recognized epitope is located in the collagen triple helix. IIF4 
and anti-collagen IV mAb recognized distinctly different epitopes. 
The significance of an anti-SCM mAb reacting with human 
collagen IV and human GBM is discussed as it pertains to molecular 
mimicry. The importance and significance of a common epitope 
between SCM and GBM is discussed in relation to development of 
poststreptococcal glomerulonephritis. A model of poststreptococcal 
glomerulonephritis is discussed with collagen IV as the autoimmune 
target reactive with anti-SCM mAb. 
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